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ABSTRACT 
The engineering of microbial cell factories capable of synthesizing industrially 
relevant chemical building blocks is an attractive alternative to conventional 
petrochemical-based production methods.  This work focuses on the novel and 
enhanced biosynthesis of phenol, catechol, and muconic acid (MA).  Although the 
complete biosynthesis from glucose has been previously demonstrated for all three 
compounds, established production routes suffer from notable inherent limitations.  
Here, multiple pathways to the same three products were engineered, each 
incorporating unique enzyme chemistries and/or stemming from different endogenous 
precursors.  In the case of phenol, two novel pathways were constructed and 
comparatively evaluated, with titers reaching as high as 377 ± 14 mg/L at a glucose 
yield of 35.7 ± 0.8 mg/g.  In the case of catechol, three novel pathways were 
engineered with titers reaching 100 ± 2 mg/L.  Finally, in the case of MA, four novel 
pathways were engineered with maximal titers reaching 819 ± 44 mg/L at a glucose 
yield of 40.9 ± 2.2 mg/g.  Furthermore, the unique flexibility with respect to 
engineering multiple pathways to the same product arises in part because these 
compounds are common intermediates in aromatic degradation pathways.  Expanding 
on the novel pathway engineering efforts, a synthetic ‘metabolic funnel’ was 
subsequently constructed for phenol and MA, wherein multiple pathways were 
expressed in parallel to maximize carbon flux toward the final product.  Using this 
novel ‘funneling’ strategy, maximal phenol and MA titers exceeding 0.5 and 3 g/L, 
respectively, were achieved, representing the highest achievable production metrics 
products reported to date.  
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1. CREATING PATHWAYS TOWARDS AROMATIC BUILDING BLOCKS AND 
FINE CHEMICALS 
 
Abstract 
Aromatic compounds represent a broad class of chemicals with a range of 
industrial applications, all of which are conventionally derived from petroleum 
feedstocks. However, owing to a diversity of available pathway precursors along with 
natural and engineered enzyme ‘parts’, microbial cell factories can be engineered to 
create alternative, renewable routes to many of the same aromatic products. Drawing 
from the latest tools and strategies in metabolic engineering and synthetic biology, 
such efforts are becoming an increasingly systematic practice, while continued efforts 
promise to open new doors to an ever-expanding range and diversity of renewable 
chemical and material products. This chapter will highlight recent and notable 
achievements regarding the microbial production of aromatic chemicals and provide 
an organizational outline of this dissertation.   
 
This chapter was published as:   
Thompson, B., Machas, M., Nielsen, D.R. Creating Pathways Towards Aromatic Building 
Blocks and Fine Chemicals (2015).  Curr Opin Biotechnol, 36:1-7.  
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1.1. Introduction 
As the focus of many researchers in the biorenewables sector continues to 
transition from biofuels to biochemicals, the motivation behind the shift is clear: bulk 
and fine chemicals are of higher value than fuels (per unit mass) and serve significantly 
smaller markets (based on total carbon demand). Thus, although the total chemicals 
market utilizes only 5% as much carbon, the net economic value nearly equals that of 
fuels (Nikolau et al. 2008). As a result, aggressive growth in this sector has been 
experienced worldwide in recent years – a trend that is expected to continue.  In the 
United States, for example, production targets of bio-based chemicals and materials 
have been set at 18 and 25% of total production levels by 2020 and 2030, respectively 
(Perlack et al. 2005).   In Europe, meanwhile, net chemical production from biomass 
is expected to reach 30% by 2030 (up from 10% in 2013) (Council 2006).  In addition 
to the continued development of established bioproducts, further growth and 
diversification amongst the renewable biochemicals market will occur most 
significantly through the engineering of novel microbial biocatalysts capable of 
synthesizing new and useful products as renewable replacements to conventional 
petrochemicals. Several recent examples illustrate how this approach has already been 
used to broaden the spectrum of chemical products that can synthesized from 
renewable biomass, including 1,4-butanediol (Yim et al. 2011), iso-butanol (Atsumi et 
al. 2010), isoprene (Zhao et al. 2011), and various organic acids (Adkins et al. 2013; 
Shiue and Prather 2014; Zhang et al. 2011).  
Aromatic compounds represent another important class of conventional 
petrochemicals that have recently emerged as promising targets for metabolic 
pathway engineering. Conventionally derived from non-renewable petroleum 
feedstocks including benzene, toluene, and xylenes (BTX), aromatic chemicals serve 
a vast market and find extensive applications in the production of various solvents,  
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plastics, and fine chemicals (Myers 2007). In 2010, for example, global annual 
consumption of benzene alone was estimated at over 40 million tons and growing 
steadily (Nexant 2011). Using microbes such as Escherichia coli and Saccharomyces 
cerevisiae as hosts, novel enzyme pathways are alternatively being engineered to 
enable the novel biosynthesis of an increasing array of aromatic chemicals directly 
from renewable, biomass-derived feedstocks (Figure 1.1). In general, the novel ability 
of microbes to produce aromatic biochemicals has been accomplished through either 
a) the functional reconstruction of natural-occurring pathways (typically from higher 
and/or less tractable organism; e.g., plants and fungi) or b) de novo pathway 
engineering.  Supported by advancements in bioinformatics, systems and synthetic 
Figure 1.1  Metabolic Network of Aromatic Biosynthesis Pathways.By applying 
metabolic engineering and synthetic biology tools, researchers have engineered a 
collective ‘network’ of biosynthetic pathways to enable the microbial biosynthesis of 
an array of useful aromatic chemicals from renewable, biomass-derived sugars. 
Illustrated are both functionally reconstructed, naturally occurring pathways as well 
as novel, non-natural pathways.  Shaded regions depict endogenous metabolism. 
Note: Trp derived pathways are excluded for clarity and space.  
 
4 
biology, protein engineering, and ‘omics’ tools, the latter approach continues to 
emerge as an increasingly systematic practice, and one that is uniquely enabling the 
biosynthesis of non-natural aromatic chemicals.  This short review aims to provide an 
overview of recent and impactful efforts to this end, with particular emphasis given to 
enabling factors uniquely associated with the biosynthesis of aromatic chemicals. 
 
1.2. A Diverse Precursor Pool Supports a Range of Aromatic Products 
With few exceptions (perhaps only phloroglucinol, a phenolic compound derived 
directly from malonyl-CoA (Achkar et al. 2005)), aromatic pathways have been 
constructed by utilizing endogenous precursors derived from the ubiquitous shikimate 
pathway.  Accordingly, achieving appreciable production of any aromatic target first 
requires metabolite flux to be enhanced through this otherwise tightly regulated 
pathway: a prerequisite condition that has been met in numerous microbial platforms, 
typically as a result of both combinatorial (e.g., metabolic evolution) and rational 
approaches (Juminaga et al. 2012; McKenna et al. 2014; Santos et al. 2012).  A key 
and relatively unique factor enabling access to a broad range of established and 
putative final aromatic products is in fact the diverse pool of uniquely functionalized 
metabolites that can serve as pathway precursors (Figure 1.1) – namely those between 
3-dehydroshikimate (3-DHS) and the terminal aromatic amino acid (AAA) products 
(i.e., tyrosine (Tyr), phenylalanine (Phe), and tryptophan (Trp)).  Lying at a highly 
regulated metabolic node, chorismate serves as a particularly useful precursor to 
numerous aromatic pathways. Meanwhile, with conserved 4-hydroxyl functionality, 
phenolic products have typically been derived from the Tyr branch, including phenol 
(Kim et al. 2014), p-hydroxybenzoate (Williams et al. 2015), coumaric acid (Vargas-
Tah et al. 2015) caffeic acid (Kang et al. 2012; Zhang and Stephanopoulos 2013), 
ferulic acid (Kang et al. 2012), p-hydroxystyrene (Qi et al. 2007), tyrosol (Satoh et al. 
5 
2012a), and hydroxytyrosol (Satoh et al. 2012b).  Stemming from the Phe branch, 
pathways have been engineered to 2-phenylethanol (Kang et al. 2014; Koma et al. 
2012), cinnamic acid (Vargas-Tah et al. 2015), styrene (McKenna and Nielsen 2011; 
McKenna et al. 2014), (S)-styrene oxide (McKenna et al. 2013), (R)-1,2-
phenylethanediol (McKenna et al. 2013), (S)- and (R)-mandelic acid (Sun et al. 2011), 
and benzaldehyde (Kunjapur et al. 2014).  Although comparatively fewer routes have 
to date been constructed from the Trp branch, notable examples include indigo dye 
(Berry et al. 2002) and catechol (though subsequently converted to muconic acid) 
(Sun et al. 2013).   
 
1.3. Constructing Aromatic Biosynthesis Pathways from Robust Enzyme 
‘Parts’ 
With a vast and comprehensive ‘toolkit’ of known and/or putative enzyme 
chemistries – including those with high chemo-, regio-, and/or stereo-specificity – 
efficient construction of aromatic biosynthetic pathways is further supported by the 
availability of an abundance of useful enzyme ‘parts’. In this case, inherent metabolic 
diversity draws from both anabolic and catabolic processes, co-evolved predominantly 
as a result of plant-microbe interactions. Within the rhizosphere and throughout the 
soil environment, for example, secondary aromatic metabolites synthesized by plant 
pathways (e.g., phenolic signaling and defense molecules, as well as lignin) (Douglas 
1996; Herrmann 1995) are ultimately assimilated and catabolized via a series of 
microbial ‘funneling pathways’ (Linger et al. 2014).  Adding to this are additional 
enzymes and pathways disparately evolved to detoxify (Beekrum et al. 2003; Stratford 
et al. 2007) and/or degrade (Diaz 2004) other, often xenobiotic, aromatic compounds.  
In many cases, it is often hydroxyl group functionality at the 4- (or p-) position 
that is found to be a strong determinant of enzyme substrate specificity.  For example, 
6 
while various Gram-positive bacteria have emerged as troves of broad specificity 
aromatic acid decarboxylases, said activities are typically limited only to substrates 
with 4-hydroxyl functionality (e.g., ferulic acid, caffeic acid, and others) (Tran et al. 
2008).  In contrast, meanwhile, phenylalanine ammonia lyases (PALs) from 
dicotyledonous plants (including those from A. thaliana), maintain a strict specificity 
for Phe and display little to no tyrosine ammonia lyase (TAL) activity (i.e., are 
incompatible with 4-hydroxyl functionalized substrates) (Cochrane et al. 2004).  
Interestingly, in one study it was shown that PAL vs. TAL activity could ultimately be 
controlled by changing single residue in the substrate binding pocket: a hydrophobic 
residue (Phe) gives rise to PAL activity, while a residue that promotes hydrogen 
bonding (His) results in TAL activity (Watts et al. 2006).   
Such examples of protein engineering to successfully control substrate 
specificity are rare, however, and, as a result of such behaviors, a priori selection of 
Figure1.2  Chorismate Derived Aromatic Biosynthesis.Enzyme ‘parts’ with broad 
substrate specificity have, in some cases, been exploited to allow engineered 
pathways to be leveraged for targeting additional products of interest.  In other 
cases, however, biosynthesis of analogous products requires the construction of 
unique enzyme pathways. 
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candidate enzymes remains a challenge with respect to the engineering of aromatic 
pathways. An example of this is seen when comparing recent efforts to engineer 
pathways towards p-hydroxystyrene and styrene – two aromatics used extensively in 
plastics production (McKenna and Nielsen 2011; Qi et al. 2007). Despite involving 
analogous structures and requisite enzyme chemistries, their individual biosynthesis 
was only possible by engineering two unique pathways (PAL/TAL and padC vs. PAL2 
and FDC1, respectively), neither of which was found to display any significant mutual 
compatibility (Figure 1.2). 
 
1.4. Exploiting Modularity to Enhance and Expand Aromatic Chemical 
Production 
One effective and emerging approach in pathway engineering that has proven 
particularly useful for producing aromatic chemicals involves discretizing pathways into 
a series of complementary modules.  Juminaga et al., for example, applied this 
strategy to enhance the native production of tyrosine by optimizing relevant 
expression parameters (Juminaga et al. 2012).  The tyrosine pathway was split at 
shikimate into upper and lower modules to enable efficient flux debottlenecking as a 
result of optimized relative plasmid copy number and promoter strength.  The same 
approach has also been successfully applied to improve E. coli’s ability to synthesize 
(2S)-pinocembrin – a flavonoid of pharmaceutical interest derived from Phe (via 
cinnamic acid; Figure 1.1) – by as much as 56-fold (Wu et al. 2013).   
In addition to promoting enhanced flux, modular approaches to pathway 
engineering further facilitate the ability by which additional aromatic products can be 
systematically targeted.  For example, facile, step-wise extension of existing pathways 
can be performed to introduce additional product functionality. The authors have 
explored this prospect, for example, by demonstrating how the chiral aromatic fine 
8 
chemicals (S)-styrene oxide and (R)-1,2-phenylethanediol can both be synthesized by 
single-step extensions of the previously-engineered styrene pathway (McKenna et al. 
2013).  More significantly, by leveraging common intermediates, the ‘plug and play’ 
assembly of different yet complementary pathway modules allows metabolite flux to 
be easily redirected towards range of alternative end products. Wang et al., for 
example, recently developed a library of mutually compatible ‘biosynthetic bricks’ for 
constructing modular pathways towards several phenylpropanoid derivatives (Wang et 
al. 2015).   By this approach, a total of four phenylpropanoic acids (cinnamic acid, p-
coumaric acid, caffeic acid, and ferulic acid), three stilbenoids (resveratrol, piceatannol 
and pinosylvin), and three curcuminoids (curcumin, bisdemethoxycurcumin and 
dicinnamoylmethane) were synthesized by E. coli.   
Another excellent application of modular pathway engineering to enhance the 
bioproduction of aromatic chemicals is also seen in the recent works of Koma et al. 
(Koma et al. 2012).  In said study, a suite of interrelated, heterologous pathways was 
engineered in E. coli to enable the individual biosynthesis of several unique aromatic 
alcohol and acid products (Figure 1.2). By employing the heterologous Ehrlich 
pathway, the flavor/fragrance compound 2-phenylethanol was first synthesized from 
endogenous phenylpyruvate.  Then, following elimination of endogenous aldehyde 
reductase activity and over-expression of phenylacetaldehyde dehydrogenase, the 
common intermediate 2-phenylacetaldehyde was further leveraged to enable the 
alternative biosynthesis of 2-phenylacetate, a drug precursor. Meanwhile, 
phenylpyruvate was also alternatively and directly reduced to 2-phenyllactate using a 
lactate dehydrogenase with broad substrate specificity from Cuprvidus necator.  
Furthermore, in contrast to the above examples of rigid rules for natural substrate 
specificity surrounding 4-hydroxyl functionality, the same broad specificity pathway 
enzymes, were analogously applied to construct mirroring pathways that stemmed 
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instead from 4-hydroxyphenylpyruvate (4HPP; Figure 1.2).  As a result, it was 
demonstrated that the same engineered pathways could be further leveraged to 
achieve the additional biosynthesis of phenolic analogs of the same three products.  
 
1.5. Multiple Pathways, One Product 
Another recent and notable development associated with the bioproduction of 
aromatic chemicals involves the engineering of multiple distinct routes to the same 
terminal product. Utilizing different precursors and/or associated chemistries, 
alternative pathways can provide effective options for circumventing inherent 
limitations of established routes. Recent examples of this trend have been seen in the 
case of both caffeic acid (Lin and Yan 2012) and 2-phenylethanol (Achmon et al. 2014; 
Masuo et al. 2015).  However, just as in natural ‘funneling pathways’, the most 
significant examples of this trend to date have predominantly involved the engineering 
of pathways to phenolic products.  For example, as originally demonstrated in 
Pseudomonas putida and more recently applied to E. coli, the biosynthesis of phenol 
– a versatile commodity chemical used widely in plastics production – has traditionally 
been achieved from endogenous Tyr via the action of tyrosine phenol lyase (TPL) (Kim 
et al. 2014).  However, TPL is both reversible (actually favoring Tyr formation) and 
subject to feedback inhibition by phenol, and has accordingly been suggested as the 
principal limiting factor in phenol bioproduction (Wierckx et al. 2008).  Recent efforts 
by Miao et al. have shown that TPL can be bypassed en route to phenol biosynthesis 
via an alternative pathway that stems instead from chorismate, proceeding via the 
intermediate p-hydroxybenzoate (Figure 1.3) (Miao et al. 2015a). 
Catechol provides another example of a phenolic compound that has been 
targeted by multiple unique routes thanks to pathway engineering.  Though typically 
explored as a precursor to muconic acid, catechol is itself useful for the synthesis of 
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fine chemicals, flavors/fragrances, and pharmaceuticals. While the classical pathway 
to catechol utilizes DHS as its immediate endogenous precursor, several unique and 
alternative routes have recently been reported (Averesch and Krömer 2014; Lin et al. 
2014; Pugh et al. 2014; Sun et al. 2013; Sun et al. 2014), all of which stem instead 
from chorismate and thereby mitigate the auxotrophy limitations associated with 
original, DHS-derived pathway. 
 
Figure 1.3  Phenol Biosynthesis Pathways.The biosynthesis of phenol has 
traditionally been achieved with the use of tyrosine phenol lyase (TPL).  To 
circumvent inherent shortcomings of TPL, however, an alternative has been 
constructed comprised of chorismate pyruvate lyase (CPL) and 4-
hydroxybenzoate decarboxylase (HBDC).    
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1.6. Inherent Challenges, Future Outlooks, and Conclusions 
Whereas continued pathway engineering efforts will undoubtedly support a 
further expanding portfolio of renewable aromatic products, the ability to achieve 
economical production metrics for both existing and future targets will likely remain a 
challenge due to several inherent limitations.  Toxicity is a common challenge for most 
aromatics, and one that limits achievable product titers (McKenna et al. 2013; Ramos 
et al. 2002).  It may be possible o address this issue, however, by taking cues from 
nature.  For example, many wild-type microbes have evolved inherent tolerances to a 
variety of aromatics (e.g., Pseudomonas sp.), and do so by fortifying their membrane 
structure and/or actively expelling species from within with the aid of efflux pumps 
(Isken and de Bont 1998; Ramos et al. 2002).   
Meanwhile, among all proteinogenic amino acids, Tyr, Phe, and Trp biosynthesis 
carry the greatest metabolic costs, and, as a result, are consequently among the least 
abundant amino acids in most wild-type systems (Akashi and Gojobori 2002).  
Accordingly, significant host engineering is typically necessary to ensure an adequate 
supply of the requisite pathway precursor.  While this problem has been addressed in 
several common laboratory strains, the same cannot be said with respect to other 
emerging and/or industrial hosts. Furthermore, aerobic conditions are typically 
required to provide adequate ATP needed for AAA biosynthesis, which, in addition to 
increasing production costs, also supports robust biomass production – a significant 
competitor for available nutrients that challenges the ability to achieve near-theoretical 
product yields.  However, with only modest maximum theoretical glucose yields (e.g., 
0.57, 0.57, and 0.44 mol/mol for Tyr, Phe, and Trp, respectively) (Kaleta et al. 2013), 
even meeting such a mark does not ensure economic viability of most prospective 
aromatic products.  Accordingly, fine and specialty aromatic products are likely to 
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emerge as the first industrial successes while commodities, at least for now, are likely 
to face challenges with respect to commercialization.  
Aromatic compounds represent a useful and versatile class of chemicals that 
have emerged as promising targets for metabolic pathway engineering. Although 
inherent limitations may challenge the microbial biosynthesis of all but fine chemical 
targets to economically-viable levels in the near term, several unique and enabling 
factors render these aromatic compounds as fertile ground for continued fundamental 
pursuits in pathway engineering. 
  
1.7. Dissertation Organization 
This dissertation is organized into five chapters.  Chapter 1 provides a brief 
introduction to and motivation for the microbial biosynthesis of aromatic compounds, 
highlighting notable achievements and current limitations associated with engineering 
aromatic biosynthesis routes. Chapter 2 explores the engineering of two novel routes 
for the biosynthesis of phenol from glucose and offers a comparison to the established 
route.  Further building upon these efforts, Chapter 3 investigates the development of 
four novel muconic acid (MA) biosynthesis pathways and provides similar comparisons 
with the established route. To maximize precursor assimilation in support of the 
biosynthesis of phenol, MA, and other potential bioproducts of interest, Chapter 4 
introduces and explores the merits of a new metabolic engineering concept: synthetic 
‘metabolic funneling’. Finally, Chapter 5 offers an outlook on potential future work 
focused on phenotype control switch mechanisms for dynamic carbon flux regulation 
to further increase production metrics of phenol, MA, and other compounds. Taken 
together, this dissertation demonstrates renewable phenol and MA production 
exceeding previously reported efforts while identifying key opportunities for further 
increases to relevant production metrics.  
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2. ENGINEERING AND COMPARISON OF NON-NATURAL PATHWAYS FOR 
MICROBIAL PHENOL PRODUCTION 
 
Abstract 
The non-renewable petrochemical phenol is used as a precursor to produce 
numerous fine and commodity chemicals, including various pharmaceuticals and 
phenolic resins.  Microbial phenol biosynthesis has previously been established, 
stemming from endogenous tyrosine via tyrosine phenol lyase (TPL). TPL, however, 
suffers from feedback inhibition and equilibrium limitations, both of which contribute 
to reduced flux through the overall pathway.  To address these limitations, two novel 
and non-natural phenol biosynthesis pathways, both stemming instead from 
chorismate, were constructed and comparatively evaluated.  The first proceeds to 
phenol in one heterologous step via the intermediate p-hydroxybenzoic acid, while the 
second involves two heterologous steps and the associated intermediates 
isochorismate and salicylate.  Maximum phenol titers achieved via these two 
alternative pathways reached as high as 377 ± 14 and 259 ± 31 mg/L in batch shake 
flask cultures, respectively. In contrast, under analogous conditions, phenol production 
via the established TPL-dependent route reached 377 ± 23 mg/L, which approaches 
the maximum achievable output reported to date under batch conditions. Additional 
strain development and optimization of relevant culture conditions with respect to each 
individual pathway is ultimately expected to result in further improved phenol 
production.   
 
This chapter was published as: 
Thompson, B., Machas, M., Nielsen, D.R. Engineering and Comparison of Non-natural 
Pathways for Microbial Phenol Production (2015). Biotech Bioeng, 113(8):1745-1754.  
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2.1. Introduction 
Phenol is an aromatic commodity chemical used widely as a versatile building 
block molecule for the synthesis of various plastics, phenolic resins, synthetic fibers, 
and most notably, bisphenol A (Weber et al. 2000).  However, as all phenol is 
conventionally derived from various petrochemical feedstocks (including benzene, 
toluene, and propylene) (Weber et al. 2000), current production routes are non-
renewable and thus unsustainable.  To address this limitation, several researchers 
have explored alternative routes for phenol production directly from renewable 
resources, most notably biomass-derived sugars, through the engineering and use of 
microbial biocatalysts.   
The first engineered pathway for phenol biosynthesis from glucose was 
reported by Wierckx et al. using Pseudomonas putida S12, a naturally solvent tolerant 
microbe, as the host platform (Wierckx et al. 2005).  Phenol was synthesized from 
endogenous tyrosine by expression of a heterologous tyrosine phenol lyase (TPL), 
encoded by the gene tpl from Pantoea agglomerans (Figure 2.1).  Random 
mutagenesis and antimetabolite selection were applied to deregulate native tyrosine 
biosynthesis, thus improving its endogenous availability and achievable phenol 
production metrics.  Ultimately, phenol production from glucose was demonstrated in 
batch shake flask cultures with titers reaching 141 mg/L at a glucose yield of 0.034 
g/g.  Subsequent adoption of a fed-batch operating protocol then ultimately enabled 
phenol production at up to 471 mg/L.  More recently, the same pathway was also 
reconstructed in Escherichia coli, in this case using Pasteurella multocida 36950 as the 
source of the tpl gene (Kim et al. 2014).  A total of 18 different E. coli strains were 
evaluated as potential hosts, including each of K-12, B, and W strains as well as a K-
12/B hybrid. In this case, tyrosine over-production was systematically engineered 
using synthetic small regulatory RNA (sRNA) to knock-down expression of two key 
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tyrosine biosynthesis pathway regulators (tyrR and csrA) while also over-expressing 
several other genes in the tyrosine biosynthesis pathway (namely, wild-type tktA, 
ppsA, aroF, aroK, and tyrC, along with feedback resistant mutants of aroG and tyrA) 
to overcome additional flux bottlenecks. Using E. coli BL21 as the host, phenol titers 
in shake flask cultures ultimately reached up to 419 mg/L under batch conditions, with 
fed-batch operation enabling production at up to 1.69 g/L at a glucose yield of 0.0026 
g/g.  For comparison, the maximum theoretical yield of phenol from glucose via said 
pathway has been reported as 0.38 g/g (Kim et al. 2014), as calculated using the E. 
coli genome-scale model EcoMBEL979 (Reed et al. 2003).  
Despite these important results, the established phenol biosynthesis pathway 
is known to suffer from several fundamental shortcomings that limit its current efficacy 
and future prospects.  First, as indicated by its positive change in Gibbs free energy 
due to reaction (ΔrG'° = +27.9 kJ/mol) in Figure 2.1, the reaction catalyzed by TPL is 
reversible and actually favors tyrosine formation.  In fact, owing to this feature, TPL 
has long been exploited as an alternative enzymatic route for synthesizing tyrosine 
from exogenous phenol (Nagasawa et al. 1981; Para et al. 1985), as well as various 
non-canonical amino acids from other phenolic substrates (e.g., catechol) (Foor et al. 
1993).  Second, TPL is known to be subject to feedback inhibition which is caused by 
phenol at relatively low concentrations.  For example, in the presence of just 94 mg/L 
phenol, it has been shown that TPL retains only 23% of its maximal activity (i.e., in 
the absence of phenol) (Wierckx et al. 2008).  For these reasons, Wierckx et al. 
specifically pointed to TPL as the limiting factor for phenol production by P. putida 
(Wierckx et al. 2008).  In the case of E. coli, these limitations are clearly manifested 
in the form of low pathway efficiency due to a metabolite flux bottleneck at the final 
step.  More specifically, although Kim et al. were able to achieve phenol production at 
up to 419 mg/L in batch cultures, between 60 and 350 mg/L of unconverted tyrosine 
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was also observed to terminally co-accumulate in the culture medium (Kim et al. 
2014).  Though not specifically emphasized in their study, these outcomes were likely 
the result of low TPL activity. 
 
 
Figure 2.1  Engineered Phenol Biosynthesis.Three non-natural pathways engineered 
for phenol production from glucose. Black arrows represent enzyme steps native to 
E. coli whereas gray arrows are heterologous; bold dotted arrows represent multiple 
enzymatic steps. ΔrG'° is the change in Gibbs free energy due to reaction as 
determined using the online tool eQuilibrator (http://equilibrator.weizmann.ac.il) at 
a reference state of 25oC, pH 7, and ionic strength of 0.1 M.  G3P: D-glyceraldehyde 
3-phosphate. F6P: β-D-fructofuranose 6-phosphate. E4P: D-erythrose 4-phospahte. 
PYR: pyruvate. PEP: phosphoenolpyruvate. DAHP: 3-deoxy-D-arabino-
heptulosonate-7-phosphate. PP: phenylpyruvate. 4HPP: 4-hydroxyphenylpyruvate. 
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In light of these limitations, it was postulated that the development of a TPL-
independent biosynthesis pathway would constitute an effective approach towards 
improving the microbial production of renewable phenol.  Accordingly, as illustrated in 
Figure 2.1, two novel and non-natural phenol biosynthesis pathways were proposed 
and investigated to this end.  In contrast to the established route (Pathway 1), both 
novel pathways stem instead from chorismate as their immediate endogenous 
precursor.  In the proposed Pathway 2, chorismate is first converted to isochorismate 
by isochorismate synthase, isochorismate is then converted to salicylate by 
isochorismate pyruvate lyase, and finally salicylate is transformed to phenol by 
salicylate decarboxylase.  In the proposed Pathway 3, chorismate is first converted to 
p-hydroxybenzoate by chorismate pyruvate lyase before p-hydroxybenzoate is 
subsequently transformed to phenol by p-hydroxybenzoate decarboxylase.  Similar to 
the established phenol pathway (Pathway 1), Pathway 3 involves the expression of a 
single heterologous enzyme, whereas Pathway 2 involves two heterologous steps 
(note: E. coli possesses a native chorismate pyruvate lyase, ubiC, and two 
isochorismate synthase genes, entC and menF).  In addition, both Pathway 2 and 3 
terminate via decarboxylation reactions which, unlike TPL, are rendered as essentially 
irreversible due to the release of CO2 gas from the culture medium (Shen et al. 2011).  
Thus, in contrast to Pathway 1, greater conversion efficiency through said novel routes 
was expected as a result.  With these factors in mind, the focus of the present study 
was to systematically construct and then comparatively evaluate the performance of 
the two novel phenol biosynthesis pathways with the goal of understanding if and how 
well their perceived inherent advantages can ultimately be translated into enhanced 
phenol biosynthesis relative to the established route. 
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2.2. Materials and Methods 
2.2.1. Bacterial Strains and Media 
All strains used in this study are listed in Table 2.1. Strains were routinely 
cultured in Luria-Bertani (LB) broth at 32ºC supplemented with 100 mg/L ampicillin, 
35 mg/L kanamycin, and/or 34 mg/L chloramphenicol, as appropriate.  To test for 
phenol production, relevant strains were cultured at 32ºC in a phosphate-limited 
minimal media composed of (concentrations in parentheses, all in g/L): MgSO4·7H2O 
(0.5), (NH4)2SO4 (4.0), MOPS (24.7), KH2PO4 (0.3), K2HPO4 (0.7), (NH4)6Mo7O24∙4H2O 
(3.7·10-4), H3BO3 (2.5·10-3), CoCl2∙6H2O (7.14·10-4), CuSO4 (1.6·10-4), MnCl2∙4H2O 
(1.6·10-3), ZnSO4∙7H2O (2.88·10-4), FeCl3 (5.0·10-5), and glucose (20), supplemented 
with appropriate antibiotics.  E. coli NEB10-beta (New England Biolabs (NEB), Ipswich, 
MA) was used for all cloning work and plasmid propagation.  Pseudomonas aeruginosa 
PAO1 was obtained from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany) and served as the 
genetic source for pchB, which encodes isochorismate synthase activity.  Citrobacter 
braakii (ATCC 29063) was obtained from the American Type Culture Collection (ATCC, 
Manassas, VA) and served as the genetic source of tutA, which encodes TPL activity.  
E. coli BW25113 was obtained from the Coli Genetic Stock Center (CGSC, New Haven, 
CT) and served as the genetic source of ubiC, which encodes chorismate pyruvate 
lyase activity, in addition to entC and menF, which both individually encode 
isochorismate synthase activity.  Klebsiella pneumoniae PZH572 (ATCC 25955) was 
obtained from the ATCC and served as the genetic source of kpdBCD, which encodes 
pHBA decarboxylase activity.  Bacillus subtilis (ATCC 31002) was obtained from the 
ATCC and served as the genetic source of bsdBCD, which also encodes p-
hydroxybenzoate decarboxylase activity.   
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2.2.2. Plasmid Construction 
All plasmids constructed and/or used in this study are listed in Table 2.1.  
Candidate genes were PCR amplified using a BioRad iCycler system with Q5 High-
Fidelity DNA Polymerase (NEB) using standard protocols and custom DNA 
oligonucleotide primers (see Appendix A, Table A1) synthesized by Integrated DNA 
Technologies (Coralville, IA).  Genomic DNA (gDNA) was prepared from cell cultures 
using the ZR Fungal/Bacterial DNA MiniPrep (Zymo Research, Irvine, CA) according to 
manufacturer protocols.  Amplified linear DNA was purified using the Zymo Research 
DNA Clean & Concentrator kit (Zymo Research).  Purified DNA fragments and plasmids 
were digested with select restriction endonucleases (NEB) according to manufacturer 
protocols.  Digested DNA fragments were gel purified using the Zymoclean Gel DNA 
Recovery Kit (Zymo Research) and ligated with T4 DNA Ligase (NEB) according to 
manufacturer protocols.  Ligation reactions were transformed into chemically 
competent E. coli NEB10-beta and selected for by plating on LB solid agar containing 
appropriate antibiotics.  Transformant pools were screened with the use colony PCR 
and restriction digest mapping. 
 To construct the plasmids pTutA, pKpd, and pBsd, tutA, kpdBCD, and bsdBCD 
were PCR amplified from C. braakii, K. pneumoniae, and B. subtilis gDNA, respectively, 
and individually inserted into pTrcCOLAK.  To construct plasmid pSDC, SDC was PCR 
amplified from a codon-optimized and synthesized (GenScript, Piscataway, NJ) variant 
of SDC from Trichosporon moniliiforme and inserted into pTrcCOLAK. To construct 
plasmid pUbiC-Kpd, ubiC was PCR amplified from E. coli BW25113 gDNA and inserted 
to pKpd. To construct plasmid pSDC-PchB-EntC, pchB and entC were PCR amplified 
from P. aeruginosa PAO1 and E. coli BW25113 gDNA, respectively, and inserted to 
pSDC.  Plasmids pS3 and pY3 were gifts from Jay Keasling (Addgene plasmid #50596 
and #50606, respectively).  To construct pY3c, the Ptrc-aroC-aroA-aroL and lacI-Ampr-
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p15A cassettes were both individually PCR amplified using pY3 as template and 
subsequently combined by circular polymerase extension cloning (CPEC) (Quan and 
Tian 2011).  
 
2.2.3. Strain Construction 
E. coli BW25113 was individually transformed with pTutA, pSDC-PchB-EntC, 
and pUbiC-Kpd, resulting in the construction of strains TYR01, SAL01, and HBA01, 
respectively.  Strains TYR01, SAL01, and HBA01 were each individually transformed 
with pS3, resulting in the construction of strains TYR02, SAL02, and HBA02, 
respectively.  Strains TYR02, SAL02, and HBA02 were each individually transformed 
with pY3, resulting in the construction of strains TYR03, SAL03, and HBA03, 
respectively.  Strains SAL02 and HBA02 were each individually transformed with pY3c, 
resulting in the construction of strains SAL04 and HBA04, respectively.  E. coli NST74 
was individually transformed with pSDC-PchB-EntC and pUbiC-Kpd, resulting in the 
construction of strains SAL05 and HBA05, respectively.  E. coli NST74 ∆pheA was 
individually transformed with pSDC-PchB-EntC and pUbiC-Kpd, resulting in the 
construction of strains SAL06 and HBA06, respectively.  E. coli NST74 ∆pheA was co-
transformed with pY3 and pTutA, resulting in the construction of TYR06.  
 
 
  
21 
Table 2.1  Strains and Plasmids for Phenol Production 
Strains Description Source 
E. coli NEB 10-beta Δ(ara-leu) 7697 araD139  fhuA ΔlacX74 galK16 
galE15 e14-  ϕ80dlacZΔM15  recA1 relA1 endA1 
nupG  rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-mcrBC)  
NEB 
C. braakii ATCC 29063 Source of tutA ATCC 
P. aeruginosa PAO1 Source of pchB DSMZ 
E. coli BW25113 Source of ubiC and entC CGSC 
K. pneumoniae PZH572 Source of kpdBCD ATCC 
B. subtilis ATCC 31002 Source of bsdBCD ATCC 
E. coli NST74 aroH367, tyrR366, tna-2, lacY5, aroF394(fbr), 
malT384, pheA101(fbr), pheO352, aroG397(fbr) 
ATCC 
E. coli NST74 ΔpheAfbr Chromosomal deletion of pheAfbr in E. coli NST74 Pugh et al. (2014) 
SAL01 E. coli BW25113 pSDC-PchB-EntC This study 
SAL02 SAL01 pS3 This study 
SAL03 SAL02 pY3 This study 
SAL04 SAL03 pY3c This study 
SAL05 E. coli NST74 pSDC-PchB-EntC This study 
SAL06 E. coli NST74 ∆pheA pSDC-PchB-EntC This study 
HBA01 E. coli BW25113 pUbiC-Kpd This study 
HBA02 HBA01 pS3 This study 
HBA03 HBA02 pY3 This study 
HBA04 HBA02 pY3c This study 
HBA05 E. coli NST74 pUbiC-Kpd This study 
HBA06 E. coli NST74 ∆pheA pUbiC-Kpd This study 
TYR01 E. coli BW25113 pTutA This study 
TYR02 TYR01 pS3 This study 
TYR03 TYR02 pY3 This study 
TYR06 E. coli NST74 ∆pheA pTutA, pY3 This study 
Plasmid Description Source 
pTrcCOLAK ColA ori; Kanr, lacIq, Ptrc McKenna et al. 
(2013) 
pTutA tutA from C. braakii ATCC 29063 inserted into 
pTrcCOLAK 
This study 
pSDC codon-optimized variant of SDC from T. moniliiforme 
inserted into pTrcCOLAK 
This study 
pKpd kpdBCD from K. pneumoniae PZH572 inserted into 
pTrcCOLAK 
This study 
pBsd bsdBCD from B. subtilis ATCC 31002 inserted into 
pTrcCOLAK 
This study 
pSDC-PchB-EntC entC from E. coli BW25113 and pchB of P. aeruginosa 
PAO1 inserted into pSDC 
This study 
pUbiC-Kpd ubiC from E. coli BW25113 inserted into pKpd This study 
pS3 pBBR1 ori; Cmr, lacI Plac-UV5-aroE-aroD-aroBop-aroGfbr-
ppsA-tktA 
Juminaga et al. 
(2012) 
pY3 p15A ori; Ampr, lacI, Plac-UV5-tyrB-tyrAfbr-aroC T1-Ptrc-
aroA-aroL 
Juminaga et al. 
(2012) 
pY3c p15A ori; Ampr, lacI, Plac-UV5-aroC T1-Ptrc-aroA-aroL This study 
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2.2.4. Assaying Candidate Enzyme Activity Using Whole Resting Cells 
The functionality of select candidate pathway enzymes was analyzed through a 
series of in vivo resting cell assays.  E. coli BW25113 was individually transformed with 
each of pTutA, pKpd, pBsd, and pSDC.  Overnight seed cultures were prepared and 
used to inoculate (1% inoculum) 50 mL of LB in 250 mL baffled shake flasks 
supplemented with 35 mg/L kanamycin.  Shake flask cultures were induced by addition 
of 10 μL 1M IPTG upon reaching an optical density at 600 nm (OD600) ~ 0.5.  Cells 
were cultured overnight (~12 h) at 32ºC and 200 RPM, and centrifuged at 3,000 x g 
for 5 min the following morning.  Cell pellets were rinsed once with phosphate buffered 
saline (PBS) solution before then being re-suspended in 50 mL PBS in a 250 mL baffled 
shake flasks at an OD600 of ~4.0.  Tyrosine was added to an initial concentration of 
2.5 mM, while p-hydroxybenzoate, and salicylate were added to initial concentrations 
of 2.5 and 5 mM before then incubating said resting cell cultures at 32ºC with shaking 
at 200 RPM for up to 48 h. Aqueous samples (0.5 mL) were periodically removed for 
analysis of substrate and product concentrations by HPLC, as described below.  
 
2.2.5. Biosynthesis of Phenol from Glucose in Shake Flask Cultures 
Overnight seed cultures of phenol producing strains were prepared and used to 
inoculate 50 mL MM1 minimal media (1% inoculum), supplemented with 20 g/L 
glucose and appropriate antibiotics; NST74 pheA strains were supplemented with 100 
mg/L phenylalanine to account for auxotrophic conditions.  Cultures were grown in 250 
mL baffled shake flasks at 32ºC to promote shikimic acid pathway flux (Tribe 1987) 
with shaking at 200 RPM to an OD600 ~ 0.7, at which point 10μL of 1M IPTG was added. 
Culturing then continued under the same conditions for an additional 72 hours, with 
periodic sampling performed for metabolite analysis by HPLC, as described below.   
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2.2.6. HPLC Analysis 
Prior to HPLC analysis, samples were diluted with 1 N HCl and incubated at 
55°C for 30 minutes, followed by centrifugation at 11,000 x g for 3 minutes and 
subsequent supernatant transfer to glass HPLC vials. Metabolite analysis was 
performed using a Hewlett Packard 1100 series HPLC system.  Separation of 
phenylalanine, p-hydroxybenzoate, salicylate, and phenol was achieved using a 
reverse-phase Hypersil GOLD aQ C18 column (4.6 mm x 150 mm; Thermo Fisher, 
USA) operated at 45°C with a constant flow rate of 0.8 mL/min consisting of 85% 5 
mM sulfuric acid and 15% acetonitrile.  The eluent was monitored using a diode array 
detector (DAD) set at 215 nm for phenylalanine and salicylate, 260 nm for p-
hydroxybenzoate, and 275 nm for phenol.  Separation of tyrosine was achieved with 
the same column using a constant flow rate of 0.5 mL/min at 30°C with a gradient of 
water (A) methanol/0.1% TFA (B) as follows: 5% B from 0 to 8 min, 5% to 40% B 
from 8 to 13 min, 40% B from 13 to 16 min, 40 to 5% B from 16 to 21 min, 5% B for 
10 min.  The eluent was monitored using a DAD set at 215 nm.  Glucose analysis was 
performed using the same HPLC system equipped with a RID detector and an Aminex 
HPX-87H column (BioRAD, Hercules, CA) operated at 35ºC.  The column was eluted 
with a constant flow rate of 0.55 mL/min 5 mM H2SO4.  External calibrations were used 
to quantify each metabolite of interest. 
 
2.2.7. Elementary Flux Mode Analysis 
Elementary flux modes (EFMs) were computed in MATLAB R2014b (MathWorks, 
Natick, MA) using the freely available program EFMTool 4.7.1 (Terzer and Stelling 
2008), available at: http://www.csb.ethz.ch/tools/efmtool.  An E. coli stoichiometric 
network was adapted from the recent works of Averesch and Kromer (Averesch and 
Krömer 2014). Developed based on input form literature (Kromer et al. 2006) and 
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various pathway databases (Caspi et al. 2008; Kanehisa and Goto 2000; Kanehisa et 
al. 2014), said network was originally used to investigate factors influencing the 
production of muconic acid, which is similarly derived from shikimic acid precursors.  
Here, however, reactions associated with muconic acid production were replaced with 
those necessary for phenol production, according to each of the three pathways of 
interest (Figure 2.1).  The network (see Appendix A, Figure A3a-c) was comprised of 
reactions involved in central carbon metabolism, specifically including glycolysis, 
Entner-Doudoroff Pathway, pentose phosphate pathway, TCA cycle, glyoxylate cycle, 
glutamtate/glutamine interconversion, anaplerosis, and the electron transport chain.  
Biomass production is also accounted for, occurring from precursors derived from 
central metabolism.  Amino acid biosynthesis, including aromatic amino acids, was not 
included (except in the case of tyrosine production as the precursor for Pathway 1).  
 
2.3. Results and Discussion 
2.3.1. Identifying and Characterizing the Requisite Pathway Enzymes 
To circumvent the aforementioned inherent limitations associated with the 
previously established TPL-dependent phenol biosynthesis pathway (i.e., Pathway 1), 
two novel pathways (i.e., Pathways 2 and 3) were proposed, systematically 
constructed, and comparatively evaluated. Investigation of the chemistries involved in 
each case reveals that both Pathway 2 and 3 are predicted to benefit from a 16% 
greater net thermodynamic driving force (Figure 2.2) relative to Pathway 1.  More 
specifically, from the last common precursor chorismate, the net change in Gibbs free 
energy due to reaction (ΔrG'°net) through both Pathways 2 and 3 is predicted to be -
181.3 kJ/mol, compared to just -151.5 kJ/mol through Pathway 1 (determined using 
the online tool eQuilibrator (http://equilibrator.weizmann.ac.il) at a reference state of 
25oC, pH 7, and ionic strength of 0.1 M).  All three pathways are predicted to support 
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nearly equivalent theoretical yields of phenol from glucose (in each case ~75%), as 
determined via elementary flux mode analysis (see Appendix A, Table A2 and Figures 
A1-A3).  Overall, this outcome is not surprising since all three pathways are derived 
from chorismate as the common endogenous precursor and carbon is equally 
conserved in each case (with one CO2 and one pyruvate removed downstream of 
chorismate in each pathway;2.1). 
 
To construct Pathway 2, it was first necessary to identify effective candidates 
displaying each of isochorismate synthase, isochorismate pyruvate lyase, and 
salicylate decarboxylase activities.  E. coli possesses two native forms of isochorismate 
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Figure 2.2  Gibbs Free Energy.Comparing the change in Gibbs free energy 
due to reaction with progress through each of the three pathways (Pathway 
1, open circles-solid line; Pathway 2, open squares-dotted line; Pathway 3, 
open diamonds-dashed line) from chorismate (the last common precursor) 
to phenol. ΔrG'° is the change in Gibbs free energy due to reaction as 
determined using the online tool eQuilibrator at a reference state of 25oC, pH 
7, and ionic strength of 0.1 M (http://equilibrator.weizmann.ac.il). 
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synthase, encoded by menF and entC, which function as part of the menaquinone and 
enterobactin biosynthesis pathways, respectively (Dahm et al. 1998).  Menaquinone 
is an essential electron carrier used during anaerobic growth (Guest 1977), and thus 
native menF expression has been reported to occur only under anaerobic conditions 
(Buss et al. 2001).  Enterobactin is required for iron transport, and thus native entC 
expression primarily occurs in the absence of iron (Kwon et al. 1996).  As neither 
environment represents the culture conditions of interest, it was determined that basal 
levels of isochorismate synthase activity would be insufficient for supporting phenol 
production in this study.  As purified enzyme assays indicate that EntC possesses 
higher activity (Km = 11.93 μM, kcat = 2.12 s-1) than MenF (Km = 6.75 μM, kcat = 0.13 
s-1) (Lin et al. 2013), entC was selected for over-expression as part of Pathway 2.  
Meanwhile, isochorismate pyruvate lyase activity has been identified as part of various 
secondary metabolite and siderophore biosynthesis pathways in a variety of bacterial 
species, and most notably in Pseudomonas aeruginosa where it is encoded by pchB 
(Gaille et al. 2002; Lamb 2011).  As prior studies have already demonstrated that 
pchB expression in E. coli enables the efficient conversion of isochorismate to 
salicylate, with kcat estimates as high as 11.2 s-1 (Lin et al. 2013), pchB was accordingly 
selected for over-expression as part of Pathway 2.  Finally, salicylate decarboxylase 
activity has to date only been reported in the soil fungi Trichosporon moniliiforme WU-
0401 (Kirimura et al. 2010).  Encoded by SDC, salicylate decarboxylase functions as 
the first step in the native salicylate biodegradation pathway (Iwasaki et al. 2010).  As 
its recombinant function in E. coli has not before been demonstrated, a codon-
optimized variant of SDC was synthesized, cloned, and expressed in SAL01 resting 
cells in order to confirm and assess its in vivo function and activity.  As seen in Figure 
2.3, in addition to a maximum specific rate of 0.16 ± 0.02 mmol g-1 h-1, approximately 
20% and 11% of the initial 2.5 mM (345 mg/L) and 5 mM (690 mg/L) salicylate was 
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converted to phenol within 12 h, respectively.  Based on these results, SDC was chosen 
for the terminal step in Pathway 2.  
Construction of Pathway 3 first required identification of genes encoding 
chorismate pyruvate lyase and p-hydroxybenzoate decarboxylase activities.  E. coli 
possesses a native copy of chorismate pyruvate lyase, encoded by ubiC, which 
functions as part of the ubiquinone biosynthesis pathway (Siebert et al. 1994).  
Although native biosynthesis of p-hydroxybenzoate biosynthesis is highly regulated in 
E. coli (Gallagher et al. 2001), the authors have previously shown that over-expression 
of native ubiC in a ∆pheA mutant of E. coli NST74 (previously engineered 
phenylalanine over-producing strain (Tribe 1987)) enabled the production of up to 277 
mg/L p-hydroxybenzoate in shake flask cultures (Pugh et al. 2014).  Based on this 
prior result, ubiC was selected for over-expression as the first step in Pathway 3.  
Phenol can be produced from p- hydroxybenzoate via p-hydroxybenzoate 
decarboxylase, an enzyme common to numerous soil microbes that functions most 
commonly as a key step in anaerobic aromatic biodegradation (Lupa et al. 2005).  
However, whereas numerous p-hydroxybenzoate decarboxylases identified to date are 
known to exhibit partial or even complete loss of functionality when expressed under 
aerobic environments (Lupa et al. 2005; Matsui et al. 2006), notable exceptions have 
been found in the case of oxygen-insensitive forms from B. subtilis and K. pneumoniae 
(encoded by bsdBCD and kpdBCD, respectively). Both p-hydroxybenzoate 
decarboxylase encoding candidate genes were cloned and screened with respect to 
their relative activity in whole resting cells of E. coli BW25113 pBsd and E. coli 
BW25113 pKpd.  As seen in Figure 2.3B, when exogenous p-hydroxybenzoate was 
supplemented at 2.5 mM (345 mg/L) and 5 mM (690 mg/L), near stoichiometric 
conversion was achieved at both substrate levels within 12 h in the case of E. coli 
BW25113 pKpd, whereas overall conversion by E. coli BW25113 pBsd was significantly 
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less (~68%) in the same time (note: full stoichiometric conversion was ultimately 
achieved by 24 h in both cases; data not shown).  Furthermore, maximum specific 
rates of p-hydroxybenzoate decarboxylation were also measured as 3.24 ± 0.4, 4.3 ± 
0.07, and 8.9 ± 0.12 mmol g-1 h-1 for E. coli BW25113 pBsd, E. coli BW25113 pKpd 
with 2.5 mM pHBA fed, and E. coli BW25113 pKPD with 5 mM pHBA fed, respectively.  
Consequently, kpdBCD was selected for use in constructing Pathway 3. 
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Figure 2.3  Recombinant Enzyme Activity.Screening candidate pathway enzymes 
in whole resting cell assays. (A)  Conversion of 2.5 mM salicylate (solid diamond) 
to phenol (open diamond) and 5 mM salicylate (solid triangle) to phenol (open 
triangle) by E. coli BW25113 pSDC.  (B) Conversion of 2.5 mM p-hydroxybenzoate 
(pHBA; solid circle) to phenol (open circle) by E. coli BW25113 pBsd, 2.5 mM 
p¬hydroxybenzoate (pHBA; solid square, solid line) to phenol (open square, solid 
line) and 5 mM pHBA (solid square, dashed line) to phenol (open square, dashed 
line) by E. coli BW25113 pKpd.  Error bars represent one standard deviation from 
triplicate experiments. 
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2.3.2. Phenol Pathway Construction in Wild-type E. coli 
Following identification of the suitable gene candidates for all of the required 
steps, full pathways were next assembled to test for phenol biosynthesis directly from 
glucose.  To establish a performance baseline, wild-type E. coli BW25113 was used as 
the initial host background of interest.  In addition to Pathways 2 and 3, Pathway 1 
 was also constructed to provide a fair comparison against the established route for 
phenol biosynthesis.  In this case, tutA from C. braakii was selected to provide the 
needed TPL activity and its recombinant function and activity was first confirmed via a 
whole resting cell assay.  In this case, 2.5 mM (453 mg/L) exogenous tyrosine was 
converted to phenol by E. coli BW25113 pTutA within 12 h at a maximum specific rate 
of 16.6 ± 0.206 mmol g-1 h-1 (see Appendix A, Figure A2).  With all three pathways 
constructed, phenol biosynthesis directly from glucose was next evaluated.  For 
Pathway 1, initial phenol titers by strain TYR01 reached 39 ± 10 mg/L in 72 h at a 
glucose yield of 2.0 ± 0.03 mg/g (Figure 2.4).  Meanwhile, in the case of Pathway 2, 
higher initial phenol titers were achieved by strain SAL01, reaching 109 ± 16 mg/L in 
72 h at a glucose yield of 5.4 ± 0.3 mg/g (Figure 2.4).  Most notably, in the case of 
Pathway 3, strain HBA01 produced up to 259 ± 31 mg/L phenol in 72 h at a glucose 
yield of 12.9 ± 1.1 mg/g (Figure 2.4).  It is important to note that no accumulation of 
any of the intermediate metabolites associated with either Pathway 2 or 3 were 
detected in the culture medium at any time (data not shown), indicating that no 
significant flux bottlenecks were experienced.  In a wild-type host background, higher 
phenol titers achieved by Pathways 2 and 3 likely reflect the fact that chorismate (the 
immediate precursor for Pathways 2 and 3) is more prevalent than tyrosine (the 
immediate precursor for Pathway 1).  Also derived from chorismate, tyrosine 
biosynthesis is additionally subjected to strong feedback regulation at the bifunctional 
chorismate mutase/prephenate dehydrogenase, encoded by tyrA, both by allosteric 
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inhibition (Lütke-Eversloh and Stephanopoulos 2005) as well as by dual transcriptional 
regulator TyrR (Pittard et al. 2005).   
 
2.3.3. Increasing Intracellular Availability of Precursor Chorismate in 
Support of Phenol Production 
Although functionality of both Pathways 2 and 3 was successfully demonstrated, there 
remained significant room for improvement with respect to achievable phenol titers 
and yields.  As no clear flux bottlenecks were observed through either pathway, it was 
hypothesized that this was due to the limited intracellular availability of chorismate in 
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Figure 2.4  Wild-type Phenol Production.Maximum phenol produced (black) via 
Pathways 1, 2, and 3 using wild-type E. coli BW25113 as host background with 
glucose consumed (gray) after 72 hours of culturing in MM1 minimal media 
supplemented with 20 g/L glucose.  Error bars represents one standard deviation 
from triplicate experiments. 
31 
the wild-type host.  Subsequent strain engineering efforts were accordingly focused at 
improving metabolite flux towards and preserving the availability of this required 
precursor.  The flux of metabolites entering the shikimic acid pathway is initially 
regulated by feedback inhibition of each of the three 3-deoxy-D-arabinoheptulosonate 
7-phosphate (DAHP) synthase isoenzymes encoded by aroG, aroF, and aroH (as 
controlled by phenylalanine, tyrosine, and tryptophan, respectively).  Among these, 
AroG has been reported to account for ~80% of the total DAHP synthase activity in E. 
coli (Kikuchi et al. 1997).  Although its wild-type activity is completely inhibited in the 
presence of only 16.5 mg/L (0.1 mM) phenylalanine (Rodriguez et al. 2014), AroG 
feedback resistant (fbr) mutants have been isolated with the ability to tolerate up to 
1650 mg/L (10 mM) phenylalanine (Kikuchi et al. 1997). Simply over-expressing an 
aroGfbr mutant in E. coli has been shown to result in a 2.9-fold increase in DAHP 
production (Floras et al. 1996).  Furthermore, in a study focused on enhancing 
shikimate biosynthesis by E. coli, Juminaga et al. also reported that, in addition to 
over-expressing aroGfbr, further flux enhancements could be achieved by also over-
expressing wild-type copies of additional genes in the upper shikimic acid pathway 
(specifically aroE, aroD, and aroB) along with select pentose phosphate pathway genes 
(ppsA and tktA) (Juminaga et al. 2012).  In this case, said modifications were 
collectively implemented via the engineering and introduction of plasmid pS3 (Figure 
2.5).  A second plasmid module (pY3) was also constructed and used in said study to 
similarly overexpress the remaining genes in the lower shikimic acid pathway (i.e., 
shikimate through tyrosine; specifically aroL, aroA, aroC, tyrB, and a tyrosine feedback 
resistant mutant of tyrA (tyrAfbr); Figure 2.5).  Using these two plasmid modules, 
efficient flux debottlenecking and fine-tuning of relative expression levels of all 
shikimic acid pathway genes was achieved, ultimately enabling the production of over 
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2.2 g/L tyrosine from glucose at a yield of 0.44 g/g (80% the theoretical maximum 
yield) (Juminaga et al. 2012).   
The effect of enhancing chorismate biosynthesis on phenol production was first 
investigated via introduction of pS3 into SAL01, HBA01, and TYR01.  The resulting 
strains, SAL02, HBA02, and TYR02, respectively, were analogously evaluated in terms 
of phenol production, the results of which are compared in Figure 2.5.  In the case of 
Pathway 2, phenol production by SAL02 ultimately reached 130 ± 37 mg/L at a glucose 
yield of 10.6 ± 2.6 mg/g, representing 19 and 96% increases over SAL01, respectively.  
Said strategy was similar effective for enhancing phenol production via Pathway 1, 
with maximum titers by TYR02 reaching 77 ± 9 mg/L at a glucose yield of 3.9 ± 0.01 
mg/g, representing 97 and 95% increases over strain TYR01, respectively.  However, 
in the case of Pathway 3, it was interestingly found that enhancing chorismate 
availability by this strategy had the opposite effect, with achievable phenol titers by 
HBA02 decreasing to just 193 ± 10 mg/L, despite a modest (~20%) increase in yield.  
At present, the specific reason underlying this observed flux decrease in the case of 
Pathway 3 remains unclear.  
Although clearly providing initial flux enhancements towards chorismate (and 
ultimately phenol), pS3 includes only those upper shikimic acid pathway genes leading 
to shikimate, it was thus possible that the one of the remaining steps (i.e., aroL, aroA, 
or aroC) was still limiting en route to chorismate.  To provide additional copies of key 
pathway enzymes downstream of shikimate and further increase flux towards 
chorismate (and ultimately tyrosine in the case of Pathway 3), the previously 
engineered plasmid pY3 was next introduced into each of TYR02, SAL02, and HBA02. 
The resultant strains (TYR03, SAL03, and HBA03) were again evaluated in terms of 
their phenol production abilities, the results of which are summarized in Figure 2.5.  In 
the case of Pathway 1, phenol titers by strain TYR03 reached 304 ± 12 mg/L at a 
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glucose yield of 15.3 ± 0.1 mg/g, representing 679 and 665% increases over TYR01, 
respectively.  However, as in prior studies employing the TPL-dependent pathway, it 
should be noted that residual tyrosine also remained at the completion culture, in this 
case reaching up to 142 ± 30 mg/L (Figure 2.5).  Meanwhile, whereas ~100% 
increases in both titer and yield were observed in the case of Pathway 2 (between 
SAL03 and SAL01), a reduced titer was again observed for Pathway 3; in this case a 
98% decrease between HBA03 and HBA01.   
In addition to phenol, significant co-accumulation of tyrosine was also now 
observed in the case of Pathway 2 and 3 for strains carrying pY3 (with as much as 672 
mg/L tyrosine detected at the completion of SAL03 cultures; Figure 2.5).  However, in 
this case, tyrosine accumulation was not the result of an inefficient and/or reversible 
pathway enzyme, but rather resulted from the undesired co-expression of tyrAfbr on 
pY3.  Thus, using pY3 as a template, an additional plasmid module (pY3c, Figure 2.5) 
was engineered for over-expression of aroL, aroA, and aroC alone by truncating the 
expression cassette to remove both tyrB and tyrAfbr.  However, as seen in Figure 2.5, 
anticipated gains in phenol production due to preserving chorismate availability in 
SAL04 and HBA04 (harboring both pS3 and pY3c) were not ultimately realized.  In 
addition to a lack of improvement in phenol production, it was also noted that net cell 
growth by both SAL04 and HBA04 was significantly reduced (by as much as 65%) 
relative to SAL01 and HBA01, respectively (data not shown). It was hypothesized the 
increased metabolic burden (Birnbaum and Bailey 1991), caused by the need to 
simultaneously maintain and express three pathway-encoding plasmids (including two 
for precursor production alone) was a possible cause of observed reductions in cell 
fitness and limited overall phenol production.  Accordingly, alternative host strains with 
the requisite, chromosomally-integrated mutations for enhancing precursor supply 
were lastly investigated as phenol production platforms. 
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2.3.4. Further Strain Engineering in Support of Phenol Biosynthesis 
Previously engineered for phenylalanine over-production, E. coli NST74 (Tribe 
1987) was next investigated as a potential host platform for phenol production by each 
of Pathways 1-3 (Figure 2.6).  Although phenylalanine biosynthesis does not directly 
support phenol production by any of the three routes, NST74 carries the desired aroGfbr 
mutant, along with several other key mutations (see Table 2.1) stably on its 
chromosome (Tribe 1987).  While modest phenol titer and yield improvements were 
observed in the case of SAL05 versus SAL04 (see Tables 3 and 4), significant levels of 
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Figure 2.5  Host Strain Engineering to Support Phenol Production.Effects 
of different host strain engineering strategies designed to increase 
chorismate availability. Residual tyrosine (white), phenol produced 
(black), and glucose consumed (gray) following 72 hours of culturing in 
MM1 minimal media supplemented with 20 g/L glucose. Error bars 
represents one standard deviation from triplicate experiments. 
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phenylalanine (as much as 540 mg/L) were now also co-produced.  Similar to tyrosine, 
phenylalanine biosynthesis also directly competes for chorismate and should be 
disrupted.  Accordingly, with pheAfbr deleted from its chromosome, NST74 pheA was 
next investigated as a phenol production host.  In the case of Pathway 2, phenol 
production by SAL06 reached peak titers of 377 ± 14 mg/L at a glucose yield of 35.7 
± 0.8 mg/g (Figure 2.6).  Compared with SAL01, this output represents a 246 and 
561% increase in titer and yield, respectively.  Similarly, in the case of Pathway 1, 
with NST74 pheA as the host background, a modest improvement in phenol 
production was also realized, with achievable titers by TYR06 reaching up to 377 ± 23 
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Figure 2.6  Alternative Host Selection for Phenol Production.Effects of 
employing alternative host strains to reduce the metabolic burden associated 
with initial, multi-plasmid expression strategies.  Residual phenylalanine 
(hashed), residual tyrosine (white), phenol produced (black), and glucose 
consumed (gray) following 72 hours of culturing in MM1 minimal media 
supplemented with 20 g/L glucose. Error bars represents one standard 
deviation from triplicate experiments. 
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mg/L at a glucose yield of 18.7 ± 0.7 mg/g (Figure 2.6).  At this output, 867 and 835% 
increases in phenol titer and yield were achieved by strain TYR06 relative to TYR01.  
As before, however, inherent inefficiencies associated with this TPL-dependent 
pathway limited net precursor flux to phenol, with residual tyrosine remaining in the 
culture at up to 175 ± 5 mg/L (Figure 2.6).  In contrast, and as with all other strategies 
investigated herein, no observable improvements in phenol production were 
demonstrated in the case of Pathway 3, with final titers by HBA06 reaching just 149 
± 12 mg/L Figure 2.6). 
 
2.3.5. Comparing Relative Performance of Established and Novel Phenol 
Biosynthesis Pathways 
Two novel phenol biosynthesis pathways were successfully constructed and 
evaluated in terms of their phenol production potential relative to the established, TPL-
dependent route.  Ultimately, the highest achievable phenol production via the 
tyrosine-, salicylate-, and p- hydroxybenzoate-derived pathways (Pathways 1, 2, and 
3, respectively) was 377 ± 23, 377 ± 14, 259 ± 31 mg/L, respectively, with 
corresponding glucose yields of and 18.7 ± 0.7, 35.7 ± 0.8, and 12.9 ± 1.1 mg/g.  
Meanwhile, whereas phenol titers were comparable between Pathways 1 and 2, 
glucose yields were nearly 2-fold higher in the latter case.  In contrast, not only were 
glucose yields significantly lower in the case of Pathway 3, but it was further found 
that all strain engineering strategies applied in said case were ultimately and wholly 
unsuccessful (production remained highest when using the original, wild-type host 
background; HBA01).  While the underlying and associated mechanisms for now 
remain unknown, it is clear that there are a number of confounding and likely complex 
factors responsible for the reduced efficacy of this pathway. 
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Phenol production by the strains developed in this study, including by all three 
pathways, also compares well with prior reports of microbes engineered to produce 
phenol by just Pathway 1 (a maximum titer of 141 mg/L and a glucose yield of 34 
mg/g by P. putida and a maximum titer of 419 mg/L and a glucose yield of 2.6 mg/g 
by E. coli) (Kim et al. 2014; Wierckx et al. 2005).  It should be noted, however, that 
phenol titers achieved by Kim et al., although slightly higher than those demonstrated 
here, relied upon the use of glucose minimal media supplemented with 3 g/L yeast 
extract.  Thus, the resultant boost in phenol titer and yield realized in said study may 
have ultimately been due to the more abundant availability of nutrients provided by 
the yeast extract.  In contrast, in the present study, as only 0.1 g/L phenylalanine was 
supplemented to accommodate for a single phenylalanine auxotrophy, phenol was 
produced solely from glucose.  Additional studies employing the same, more complex 
medium composition would be required to further understand the importance of such 
differences.  Meanwhile, it should also be noted that analogous host backgrounds and 
culture conditions were selected in the present study in order to enable a fair, head-
to-head comparison and evaluation of the relative merits and potential pitfalls 
associated with Pathways 1-3. Overall, however, it is expected that greater overall 
phenol production in all three cases should in fact be possible through individual 
optimization of the chosen host strain and/or culture condition employed.  
Whereas a pathway to phenol via salicylate (Pathway 2) has not before been 
reported, salicylate has served as a key intermediate in support of the synthesis of 
other target chemicals of interest.  For example, Lin et al. recently reported the 
engineering of a novel pathway to muconic acid in which the intermediate salicylate is 
converted instead to catechol via salicylate monooxygenase (SMO) before catechol is 
then transformed to muconic acid by catechol 1,2-dioxygenase (CDO) (Lin et al. 2014).  
Using a pathway that was likewise composed of entC and pchB, salicylate biosynthesis 
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was first demonstrated as a terminal product, reaching titers as high as 1.2 g/L (8.7 
mM).  While this output represents a molar flux to salicylate that is ~2.2-fold greater 
than was ultimately demonstrated here (a maximum of 4.0 mM phenol produced from 
salicylate), it should be noted that said study relied upon the alternative use of a 
mixture of (in g/L) glycerol (10), glucose (2.5), and yeast extract (1) as substrates, in 
contrast to the sole use of glucose here.  As a non-phosphotransferase system (PTS) 
substrate, glycerol conserves phosphoenolpyruvate (PEP) levels in the cell and 
accordingly supports the enhanced synthesis of products derived from the shikimic 
acid pathway (Gottlieb et al. 2014).  Moreover, over-expression of native ppsA and 
tktA was also performed, strategies demonstrated to further promote the production 
PEP and erythrose 4-phosphate (E4P), respectively, the two key precursors to the 
shikimic acid pathway.  Accordingly, it is similarly expected that enhanced phenol 
production via salicylate (Pathway 2) could likewise be achieved by incorporating such 
strategies, as will be investigated in future works. 
Meanwhile, concurrent to the present study, Miao et al. also recently reported 
on the successful engineering of a pathway for phenol biosynthesis in E. coli via the 
intermediate p- hydroxybenzoate (Pathway 3, Figure 2.1) (Miao et al. 2015a).  In their 
study, however, rather than kpdBCD, ycl from E. coli W was overexpressed to convert 
p-hydroxybenzoate to phenol – an enzyme they ultimately found to be rate limiting in 
the pathway. Similar to the present study, native ubiC and aroGfbr were also co-
expressed to complete the pathway and enhance precursor supply, respectively.  In 
the end, maximum phenol titers achieved in shake flasks reached 355 mg/L (3.8 mM), 
but only when cultures were directly supplemented with 138 mg/L (1 mM) p-
hydroxybenzoate (the pathway intermediate).  More recently, while this manuscript 
was under revision, Ren et al. also reported on the construction of an alternative 
phenol biosynthesis pathway, in this case via salicylate (i.e., Pathway 2, Figure 2.1) 
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(Ren et al. 2015).  In this case, as in the present study, each of entC, pchB, and SDC 
were likewise overexpressed in E. coli resulting in the production of 406 mg/L phenol, 
or up to 472 mg/L after further optimization of the medium formulation; output levels 
that agree well with those reported herein.  
Regardless of the chosen pathway, product toxicity is a common concern 
associated with the production of aromatic chemicals (McKenna and Nielsen 2011; 
McKenna et al. 2013), including phenol (Wierckx et al. 2005).  Past reports have 
shown, for example, that E. coli growth is completely inhibited in the presence of 1.75 
g/L phenol, with overall reductions in growth also observed at lower levels (Kim et al. 
2014).  Based on this, end product toxicity was considered to be an unlikely factor 
with respect to influencing overall host fitness under the conditions examined.  
Nevertheless, as others have found the use of in situ solvent extraction to remove 
phenol from cultures as it is produced as an effective strategy for improving production 
(Miao et al. 2015a), it may prove analogously effective in the case of strains developed 
here. 
 
2.4. Conclusions 
Two non-natural and novel pathways for phenol biosynthesis were engineered 
and comparatively evaluated to understand their inherent advantages/limitations and 
to assess their performance relative to the established route.  Under otherwise 
analogous conditions, the highest achievable phenol production via the salicylate-, p- 
hydroxybenzoate-, and established tyrosine-derived pathway was 377 ± 14, 259 ± 
31, and 377 ± 23 mg/L, respectively, with corresponding glucose yields of 35.7 ± 0.8, 
12.9 ± 1.1, and 18.7 ± 0.7 mg/g.  Despite strain engineering efforts resulting in 
increased overall phenol production via the tyrosine derived pathway, TPL equilibrium 
limitations continue to limit the overall pathway efficiency.  Meanwhile, in contrast to 
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the other routes, phenol production via the p-hydroxybenzoate derived pathway was 
highest in the original wild-type host, with all efforts to increase overall pathway flux 
unsuccessful.  While this suggests that other complex regulatory factors may also be 
specifically associated with this pathway and/or its intermediates, further investigation 
will likely be required for these to be elucidated and ultimately overcome.  Lastly, it 
should also be noted that while equivalent background strains and culture conditions 
were investigated to provide a fair pathway comparison, alternative strain selection 
and optimization of culture conditions relative to each individual pathway presented 
herein may ultimately result in higher achievable phenol titers.  
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3. ENGINEERING A NETWROK OF PATHWAYS FOR THE NOVEL 
BIOSYNTHESIS OF MUCONIC ACID  
 
Abstract 
Muconic acid (MA) is promising platform biochemical and precursor to adipic 
acid, which can be used to synthesize various plastics and polymers.  Multiple 
pathways for de novo MA biosynthesis from glucose have previously been reported, 
each incorporating unique enzyme chemistries and/or stemming from different 
shikimic acid pathway precursors.  Here, three novel routes to MA were systematically 
engineered in Escherichia coli by linking a series of pathways recently constructed for 
the biosynthesis of phenol with select steps associated with its subsequent, partial 
aerobic degradation.  In addition, a fourth route to MA was also engineered, in this 
case from endogenous chorismate and proceeding via p-hydroxybenzoate, 
protocatechuate, and catechol.  Said novel pathways were comparatively evaluated 
against each other and the established, 3-dehydroshikimate-derived route, with latter 
supporting the highest MA titers and yields at 819 mg/L and 40.9 mg/g, respectively, 
as supported by both model simulations and experimental studies.  
 
Select portions of this chapter have been submitted as: 
Thompson, B., Pugh, S., Machas, M., Nielsen, D.R. Exploring Novel Pathways and 
Synthetic Metabolic Funneling to Enhance Muconic Acid Biosynthesis. Metab Eng 
(2017).   
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3.1. Introduction 
In recent years, muconic acid (MA) has continued to emerge as a diacid 
bioproduct of industrial interest, most notably due to its role as a precursor to adipic 
acid – a platform chemical used for the synthesis of various plastics and polymers 
(e.g., Nylon 6,6) (Adkins et al. 2012; Deng et al. 2016).  Through metabolic pathway 
engineering, numerous studies have reported the engineering of microbes capable of 
producing MA as the focal product from renewable feedstocks (Curran et al. 2013; 
Draths and Frost 1994; Johnson et al. 2016; Lin et al. 2014; Niu et al. 2002; Sengupta 
et al. 2015; Sun et al. 2013; Sun et al. 2014; Weber et al. 2012; Zhang et al. 2015a; 
Zhang et al. 2015c).  Draths and Frost were first to report MA biosynthesis from 
glucose in Escherichia coli, following construction of a two-step pathway stemming 
from endogenous 3-dehydroshikimate (3DHS), a key intermediate in the shikimic acid 
pathway (Draths and Frost 1994).  Said pathway, which has since also been 
functionally re-constructed in Saccharomyces cerevisiae (Curran et al. 2013; Weber et 
al. 2012), proceeds through the intermediates protocatechuate (PCA) and catechol via 
3-DHS dehydratase, PCA decarboxylase, and catechol 1,2-dioxygenase (hereafter 
referred to as ‘3DHS-derived’).  Achieving significant MA production via this pathway 
has typically required deletion of aroE (encoding shikimate dehydrogenase, an 
essential gene in minimal media).  This mutation results in auxotrophies for the 
aromatic amino acids phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp), as 
well as the growth essential vitamins p-aminobenzoate (pAB), p-hydroxybenzoate 
(pHBA), and 2,3-dihydroxybenzoate (2,3-DHB) – all of which are derived from 
chorismate as their last common precursor.  Thus, although high MA titers and yields 
have been achieved via the ‘3DHS-derived’ pathway when expressed in E. coli aroE 
backgrounds (2.4 g/L at 0.24 g/g-glucose, respectively, in shake flasks (Draths and 
Frost 1994), and 36.8 g/L at 0.17 g/g-glucose in a fed-batch bioreactor (Niu et al. 
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2002)), doing so required each of the above six nutrients to first be supplemented into 
the minimal salts media – an expensive and poorly scalable practice.   
To address this limitation, multiple alternative MA biosynthesis pathways have 
recently been engineered, each involving different enzyme chemistries and, most 
notably, stemming from precursors further downstream in the shikimic acid pathway, 
thereby preserving chorismate biosynthesis. Because native biosynthesis of each of 
Phe, Tyr, Trp, pAB, pHBA, and 2,3-DHB is tightly regulated downstream of chorismate 
(i.e., by feedback repression), potential auxotrophies for these species are effectively 
avoided with only minimal loss of MA precursors.  To date, no fewer than four 
alternatives pathways have so far been proposed and/or developed for MA biosynthesis 
from glucose (Averesch and Krömer 2014).  For example, Sun et al. recently reported 
a novel MA biosynthesis pathway utilizing anthranilate (intermediate to Trp) as its 
immediate endogenous precursor (Sun et al. 2013).  By said pathway, MA titers of 
0.39 g/L were achieved using a mixed glucose/glycerol minimal media (supplemented 
with Trp to account for deletion of trpD) in shake flask cultures.  The same group also 
later engineered another alternative MA pathway, in this case utilizing endogenous 
2,3-DHB as its immediate endogenous precursor (Sun et al. 2014).  In this case, MA 
titers of 0.48 g/L were reported using a glucose/glycerol media with yeast extract in 
shake flasks cultures.  Most recently, the same group has engineered a third, 
alternative MA pathway that instead stems directly from chorismate and proceeds via 
the key intermediates isochorismate and salicylate (Lin et al. 2014).  Said pathway 
resulted in MA titers reaching 1.45 g/L in shake flask cultures using the same 
glucose/glycerol media with yeast extract (in this case to account for Phe and Tyr 
auxotrophies caused by deletion of pheA and tyrA, respectively, to increase chorismate 
availability).  
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In addition to these novel MA biosynthesis pathways reported to date, 
alternative strategies for catechol and MA biosynthesis were investigated here by: i) 
constructing a series of modular, phenol-derived catechol and MA pathways by linking 
three recently engineered phenol biosynthesis pathways (Thompson et al. 2016) with 
their subsequent aerobic degradation, and; ii) engineering a four-step MA pathway 
from endogenous chorismate via the intermediates pHBA, PCA via a previously 
reported novel catechol biosynthesis pathway (Pugh et al. 2014).  Both strategies 
importantly circumvent the auxotrophic limitations experienced via the original ‘3DHS-
derived’ route. 
 
3.2. Materials and methods 
3.2.1. Strains and Media 
All strains used in this study are listed in Tables 3.1 and 3.2.  E. coli NEB10-
beta (New England Biolabs (NEB); Ipswich, MA) was used for all cloning and plasmid 
maintenance.  E. coli NST74 (ATCC 31884) was obtained from the American Type 
Culture Collection (ATCC; Manassas, VA) and served as the parent strain in this study.  
E. coli JW2580-1 was obtained from the Coli Genetic Stock Center (CGSC; New Haven, 
CT) and served as the genetic source for the pheA::KanR cassette.  E. coli BW25113 
was obtained from the CGSC and served as the genetic source for ubiC and entC.  
Citrobacter braakii (ATCC 29063) was obtained from the ATCC and served as the 
genetic source for tutA.  Klebsiella pneumoniae PZH572 (ATCC 25955) was obtained 
from the ATCC and served as the genetic source of kpdBCD and aroY.  Pseudomonas 
aeruginosa PAO1 (DSMZ 22644) was obtained from the Leibniz Institute German 
Collection of Microorganisms and Cell Cultures and served as the genetic source of 
pobA.  P. stutzeri OX1 (ATCC BAA-172) was obtained from the ATCC and served as 
the genetic source of phKLMNOP.  Pseudomonas putida KT2440 (ATCC 47054) was 
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obtained from the ATCC and served as the genetic source for catA.  Corynebacterium 
glutamicum (ATCC 13032) was obtained from the ATCC and served as the genetic 
source of qsuB.   
Seed cultures of E. coli strains were cultured in Luria-Bertani (LB) broth at 32ºC 
and supplemented with 100 mg/L ampicillin and/or 35 mg/L kanamycin, as 
appropriate.  For catechol and MA biosynthesis, shake flasks were cultured at 32ºC in 
M9M minimal media supplemented with appropriate antibiotics.  M9M was composed 
of the following (in g/L): Na2HPO4 (6), KH2PO4 (3), NaCl (0.5), NH4Cl (2), MgSO4·7H2O 
(0.493), CaCl2·2H2O (0.0147), and glucose (20).  Trace elements were supplemented 
as follows (in mg/L): (NH4)6Mo7O24∙4H2O (0.37), H3BO3 (2.5), CoCl2∙6H2O (0.714), 
CuSO4 (0.16), MnCl2∙4H2O (1.6), ZnSO4∙7H2O (0.288), FeCl3 (0.05).   
 
3.2.2. Plasmid Construction 
All plasmids used and developed in this study are listed in Table 3.1. All genes 
were PCR amplified with Q5 High-Fidelity DNA Polymerase (NEB) and a BioRad iCycler, 
per manufacturer protocols.  Custom DNA oligonucleotide primers (See Table B1, 
Appendix B) were synthesized by Integrated DNA Technologies (IDT, Coralville IA).  
Genomic DNA (gDNA) templates were prepared using the ZR Fungal/Bacterial DNA 
MiniPrep kit while plasmid DNA was purified using the Zymo Plasmid MiniPrep kit (both 
Zymo Research, Irvine CA).  Amplified linear DNA fragments were purified using the 
Zymo DNA Clean & Concentrator MiniPrep kit (Zymo Research).  Purified linear DNA 
and plasmid DNA were digested using appropriate restriction endonucleases (NEB) and 
subsequently gel purified using the Zymoclean Gel DNA Recovery MiniPrep kit (Zymo 
Research).  Purified digested DNA fragments were ligated using T4 DNA Ligase (NEB), 
per manufacturer protocols.  Ligation reactions were transformed into chemically 
competent E. coli NEB10-beta before plating on LB solid agar media supplemented 
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with appropriate antibiotics for selection.  Transformant pools were screened using 
colony PCR, restriction digest mapping, and finally confirmed by DNA sequencing.  
 
3.2.3. Strain Construction 
All strains engineered and used in this study are listed in Tables 3.1 and 3.2.  
Chromosomal in-frame deletions of pheAfbr in E. coli NST74 was constructed using a 
modified version of the Datsenko and Wanner method (Datsenko and Wanner 2000), 
as previously described (Pugh et al. 2014).  The pheA:: FRT-kanR-FRT deletion cassette 
was PCR amplified from E. coli JW2580-1.  Chromosomal integration of said cassette 
and subsequent removal of kanR marker was achieved as previously described 
(Datsenko and Wanner 2000; Pugh et al. 2014), resulting in the individual construction 
of E. coli NST74 ∆pheAfbr.  For catechol biosynthesis, E. coli NST74 ∆pheAfbr was co-
transformed with the following combinations of plasmids (note: pathway designation 
provided in parentheses): pY3 and pTutA-pPh (CAT2), pSDC-PchB-EntC and pPh 
(CAT3), pUbiC-Kpd and pPh (CAT4), and pUbiC-PobA and pAroY (CAT5).  For MA 
biosynthesis, E. coli NST74 ∆pheA was co-transformed with the following combinations 
of plasmids: pQsuB-AroY-CatA (MA1), pY3 and pTutA-pPh-CatA (MA2), pSDC-PchB-
EntC and pPh-CatA (MA3), pUbiC-Kpd and pPh-CatA (MA4), and pUbiC-PobA and 
pAroY-CatA (MA5). 
 
3.2.4. Thermodynamic and Elementary Flux Mode Analysis  
To compare relative pathway energetics, net changes in Gibbs free energy due 
to reaction, ΔrG'°net, were calculated using the online eQuilibrator tool (available at 
http://equilibrator.weizmann.ac.il) at a reference state of 25ºC, pH 7, and ionic 
strength of 0.1 M. Elementary flux modes (EFMs) were computed in MATLAB R2014b 
(MathWorks, Natick MA) using EFMTool 4.7.1 (Terzer and Stelling 2008).  An E. coli 
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stoichiometric network originally employed to compare different phenol biosynthesis 
pathways (Thompson et al. 2016) and originally adapted from Averesch and Krömer 
(2014), was used to compare relative maximum yields from the various MA pathways 
and strains of interest in this study (see Appendix B).  
 
3.2.5. Assaying Phenol Hydroxylase and Catechol 1,2-Dioxygenase Activity 
Using Whole Resting Cells 
Recombinant activities of phenol hydroxylase and catechol 1,2-dioxygenase 
were assayed in E. coli BW25113 following its transformation with pPh or pPh-CatA.  
Overnight seed cultures were used to inoculate (1% vol.) 50 mL of LB supplemented 
with 20 g/L glucose and 35 mg/L kanamycin in 250 mL shake flasks.  In addition, the 
effect of Fe(NH4)2(SO4)2 was also examined via its omission or inclusion at 100 μM. 
Shake flasks were induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) 
at a final concentration of 0.4 mM upon reaching an optical density at 600 nm (OD600) 
of 0.7.  Culturing continued overnight (~12 h) at 32ºC before cells were then collected 
by centrifugation at 3,000 x g for 5 min.  Cell pellets were rinsed twice with pH 6.8 
phosphate buffered saline (PBS) before being re-suspended to a final OD600 of 4 in PBS 
supplemented with 0.2 g/L glucose and 1 mM phenol in a 250 mL shake flask.  Cultures 
were subsequently incubated at 32ºC with shaking at 200 RPM for up to 12 hours.  
Samples were periodically drawn for metabolite quantification via HPLC, as described 
below.  
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Table 3.1  Strains and Plasmids Used for MA Production 
Strain Description Source 
E. coli NEB10-beta Δ(ara-leu) 7697 araD139  fhuA ΔlacX74 galK16 galE15 
e14- ϕ80dlacZΔM15 recA1 relA1 endA1 nupG 
rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-mcrBC)  
NEB 
E. coli BW25113 Source of ubiC and entC CGSC 
E. coli JW2580-1 Source of pheA::KanR CGSC 
E. coli NST74 aroH367, tyrR366, tna-2, lacY5, aroF394(fbr), malT384, 
pheA101(fbr), pheO352, aroG397(fbr) 
ATCC 
E. coli NST74 ∆pheA pheA chromosomal deletion in E. coli NST74 Pugh et al. (2014) 
C. glutamicum Source of qsuB ATCC 
C. braakii Source of tutA ATCC 
P. aeruginosa PAO1 Source of pobA and pchB DSMZ 
E. coli BW25113 Source of ubiC and entC CGSC 
K. pneumoniae PZH572 Source of kpdBCD and aroY ATCC 
P. stutzeri OX1 Source of phKLMNOP ATCC 
P. putida KT2440 Source of catA ATCC 
Plasmid Description Source 
pTrc99A pBR322 ori, Ampr, lacIq, Ptrc Prather Lab, MIT 
pTrcCOLAK ColA ori, Kanr, lacIq, Ptrc 
McKenna et al. 
(2013) 
pY3 
p15A, Ampr, lacI, Plac-UV5-tyrB-tyrAfbr-aroC T1-Ptrc-aroA-
aroL 
Juminaga et al. 
(2012) 
pKD46 repA101(ts) and R101 ori, Ampr, araC, araBp CGSC 
pCP20 FLP, ts-rep, [cI857](lambda)(ts), Ampr CGSC 
pTutA-Ph tutA of C. braakii inserted to pPh This study 
pTutA-Ph-CatA tutA of C. braakii inserted to pPh-CatA This study 
pSDC-PchB-EntC 
SDC of T. moniliforme, pchB of P. aeruginosa PAO1, and 
entC of E. coli BW25113 inserted to pTrc99A 
This study 
pUbiC-Kpd 
ubiC of E. coli BW25113 and kpdBCD of K. pneumoniae 
PZH572 inserted to pTrc99A 
This study 
pPh phKLMNOP of P. stutzeri OX1 inserted to pTrcCOLAK This study 
pPh-CatA catA of P. putida KT2440 inserted to pPh This study 
pUbiC-PobA 
ubiC of E. coli BW25113 and pobA of P. aeruginosa PAO1 
inserted to pTrc99A 
Pugh et al. (2014) 
pAroY aroY of K. pneumoniae PHZ572 inserted to pTrcCOLAK Pugh et al. (2014) 
pAroY-CatA catA of P. putida KT2440 inserted to pAroY This study 
pQsuB-AroY-CatA qsuB of C. glutamicum inserted to pTrc99A This study 
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Table 3.2  Strains Engineered for Catechol and MA Biosynthesis  
Pathway Plasmid Combination Source 
CAT2 pY3, pTutA-Ph This study 
CAT3 pUbiC-Kpd, pPh This study 
CAT4 pSDC-PchB-EntC, pPh This study 
CAT5 pUbiC-PobA, pAroY Pugh et al. (2014) 
MA1 pQsuB-AroY-CatA This study 
MA2 pY3, pTutA-Ph-CatA This study 
MA3 pUbiC-Kpd, pPh-CatA This study 
MA4 pSDC-PchB-EntC, pPh-CatA This study 
MA5 pUbiC-PobA, pAroY-CatA This study 
 
 
3.2.6. Catechol and MA Production from Glucose 
To investigate the bioproduction of catechol and MA, overnight seed cultures 
were first prepared in LB and supplemented with 100 mg/L ampicillin and/or 35 mg/L 
kanamycin and used to inoculate (1% vol) 50 mL of M9M minimal media supplemented 
with 20 g/L glucose in 250 mL shake flasks (note: the medium was additionally 
supplemented with 0.1 g/L Phe when using ∆pheA-derived host strains). Shake flask 
cultures were incubated at 32ºC with shaking at 200 RPM until reaching OD600 ~0.7, 
at which point IPTG induction was performed at a final concentration of 0.4 mM. 
Cultures were further incubated for a total of up to 120 h, or until significant sugar 
consumption was no longer detected.  Periodically, samples were drawn to measure 
cell growth (as OD600) sugar and metabolite levels by HPLC analysis, as described 
below.  Prior to centrifugation (i.e., to pellet and remove cells), samples for MA analysis 
were first diluted 1:10 with methanol, while samples for Tyr analysis were diluted 1:10 
with 1 N HCl and incubated at 55°C for 30 min.  All samples were then centrifuged at 
11,000 x g for 5 min before transferring the supernatant to a glass HPLC vial. 
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3.2.7. HPLC Metabolite Analysis 
Metabolite analysis was performed using a Hewlett Packard 1100 series HPLC 
system.  Separation of Phe, pHBA, PCA, salicylate, phenol, catechol, and MA, was 
achieved using a reverse-phase Hypersil GOLD aQ C18 column (3 mm x 250 mm; 
Thermo Fisher, Waltham, MA, USA) operated at 45°C with an isocratic 0.8 mL/min 
mobile phase consisting of 85% (vol.) 5 mM H2SO4 and 15% (vol.) acetonitrile.  The 
eluent was monitored using a diode array detector (DAD) set at 215 nm for Phe, 
salicylate, PCA, and catechol, 260 nm for pHBA, and 275 nm for phenol and MA.  
Separation of Tyr was also achieved on Hypersil GOLD aQ C18 column, in this case 
maintained at 30°C while using a mobile phase consisting of water (A) and methanol 
plus 0.1% (vol.) formic acid (B) at a constant flow rate of 0.2 mL/min and the following 
concentration gradient (all by vol.): 5% B from 0 to 8 min, 5% to 40% B from 8 to 13 
min, 40% B from 13 to 16 min, 40 to 5% B from 16 to 21 min, and 5% B from 21 to 
31 min.  The eluent was monitored using a DAD at 215 nm.  Glucose and acetate 
separation was achieved using an Aminex HPX-87H column (BioRAD, Hercules, CA) 
operated at 35ºC and detected using a refractive index detector (RID).  The column 
was eluted with 5 mM H2SO4 at a constant flow rate of 0.55 mL/min. In all cases, 
external standards were prepared and used to provide calibrations for concentration 
determination. 
Mass spectrometry analysis was performed using a Dionex Ultimate 3000 HPLC 
system (Bruker Daltonics, Billerica, MA, USA) consisting of a HPG-3400 M pump, WPS 
3000 TB autosampler fitted with a 5 μL sample loop, and a FLM-3100B thermostatted 
column compartment.  A Hypersil GOLD aQ C18 column (3 mm x 250 mm; Thermo 
Fisher, Waltham, MA, USA) was operated at 25°C with an isocratic 0.2 mL/min mobile 
phase consisting of 85% (vol.) 5 mM formic acid and 15% (vol.) acetonitrile.  
Metabolites were detected as negative ions using a Bruker MicrOTOF-Q mass 
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spectrometer with the following settings: Capillary voltage, +4000; end plate offset, -
500V; nebulizer gas pressure, 2.0 bar; dry gas flow, 8 L/min; dry gas temperature, 
210° C; Funnels 1 and 2 radio frequency (RF) settings, 200 Vpp, Hexapole RF setting, 
150 Vpp; Collision Cell RF setting, 100 Vpp; Quadrupole low mass setting, 55 m/z; 
Transfer time, 100 µs; Pre Pulse Storage, 7 µs.  A Peak Scientific NM30LA nitrogen 
generator (Peak Scientific Inc., Billerica, MA, USA) supplied nitrogen for the drying and 
nebulizer gases. 
 
3.3. Results and Discussion 
3.3.1. Novel Pathway Identification and Theoretical Comparison 
In addition to the original, ‘3DHS-derived’ pathway (steps A, B, C in Figure 3.1; 
hereafter referred to as MA1) (Draths and Frost 1994), as discussed above, several 
alternative pathway options for MA biosynthesis have since also been developed.  
Although proceeding from different endogenous metabolites and/or involving 
alternative enzyme chemistries, catechol always serves as the immediate MA 
precursor.  However, in addition to serving as the ubiquitous MA precursor, catechol 
is also the first intermediate associated with aerobic phenol catabolism – a degradation 
pathway common to many soil microbes, including various Pseudomonas sp., for 
example (van Schie and Young 2000).  Accordingly, it was hypothesized that, by 
linking engineered phenol production with its partial, aerobic degradation, additional 
new routes to MA could ultimately also be engineered. More specifically, as illustrated 
in Figure 3.1, this could be achieved by further co-expressing phenol hydroxylase (PH) 
and catechol 1,2-dioxygnease (CDO) (steps K, C; Figure 3.1) in a phenol-producing 
background.  Whereas engineered phenol production has traditionally involved 
expression of tyrosine phenol lyase (TPL; step J) in a Tyr overproducing host (Kim et 
al. 2014; Wierckx et al. 2005), two alternative phenol biosynthesis pathways from 
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chorismate were recently reported, involving either isochorismate synthase, 
isochorismate pyruvate lyase, and salicylate decarboxylase (steps G, H, I) or 
chorismate lyase and pHBA decarboxylase (steps D, F) (Thompson et al. 2016).  
Accordingly, three novel, phenol-dependent MA biosynthesis pathways were proposed, 
hereafter referred to as MA2 (steps J, K, C), MA3 (steps G, H, I, K, C), and MA4 (steps 
D, F, K, C).  Meanwhile, in separate works, a novel pathway for catechol biosynthesis 
was previously reported that proceeds from chorismate through pHBA and PCA via 
chorismate lyase, pHBA hydroxylase, and PCA decarboxylase (steps D, E, B) (Pugh et 
al. 2014).  Accordingly, further extension of this pathway to MA was also proposed, in 
this case by co-expressing CDO, resulting in pathway MA5 (steps D, E, B, C).  
Unlike MA1, the four alternative pathways proposed herein (MA2-5) importantly 
stem from chorismate or one of its downstream metabolites, and thereby offer 
improved host compatibility by preserving native flux through the shikimic acid 
pathway.  In addition, relative to MA1, each of MA2-5 was also found to further benefit 
from an increased net thermodynamic driving force (as much as 104% greater). More 
specifically, when evaluated from the last common precursor (i.e., 3DHS), the net 
change in Gibbs free energy due to reaction (ΔrG'°net) was predicted to be -1037.4 
kJ/mol for each of MA3-5 and -1007.6 kJ/mol for MA2, compared to just -508.5 kJ/mol 
for MA1 (Figure 3.2).  In contrast, as determined via elementary mode analysis 
(Figures B1a-e, Appendix B), MA1 supports the highest product yield, with the 
predicted maximum theoretical yields of MA from glucose (YP/S,max) being ~18% lower 
(or ~15% lower with growth, YP/S,max+growth; Figure 3.2) for each of MA2-5.  In all cases, 
said reduction is due to the additional 1 NADPH (by AroE), 1 ATP (by AroL), and 1 
phosphoenolpyruvate (PEP; by AroA) consumed while converting 3DHS to chorismate.  
Meanwhile, both MA3 and MA4 further require an additional 1 NADH (i.e., by PH; note: 
this demand is balanced in MA2 by the generation of 1 NADH by TyrA), whereas MA5 
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requires an additional 1 NADPH (by pHBA hydroxylase).  Other previously-reported 
chorismate-derived MA pathways (i.e., derived from anthranilate or from salicylate, 
via an alternative mechanism (Lin et al. 2014; Sun et al. 2013)) suffer the same 
limitations with respect to predicated maximum MA yields from glucose, in this case 
also being about 17-20% lower than MA1 (or 18-19% lower with growth; note: the 
anthranilate-derived pathway offers the lowest yield due to a requirement for an 
additional 1 ATP) (Averesch and Krömer 2014). Therefore, despite incorporating more 
favorable enzyme chemistries and the potential for improved host compatibility, 
potential improvements associated with the proposed and other MA pathways come at 
the cost of lower maximum theoretical yields.  
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Figure 3.1  Five Non-natural Pathways Engineered for Muconic Acid Biosynthesis 
Black arrows represent native E. coli enzymatic steps; gray arrows represent 
heterologous steps; dotted arrows represent multiple enzymatic steps.  ΔrG'° is 
the change in Gibbs free energy due to reaction as determined using the online 
tool eQuilibrator (http://equilibrator.weizmann.ac.il) at a reference state of 25oC, 
pH 7, and ionic strength of 0.1 M. A: 3-dehydroshikimate dehydratase, B: 
protocatechuate decarboxylase, C: catechol 1,2-dioxygenase, D: chorismate 
pyruvate lyase, E: p-hydroxybenzoate hydroxylase, F: p-hydroxybenzoate 
decarboxylase, G: isochorismate synthase, H: isochorismate pyruvate lyase, I: 
salicylate decarboxylase, J: tyrosine phenol lyase, K: phenol hydroxylase. 
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3.3.2. Screening for and Characterizing Phenol Hydroxylase Activity in E. coli 
Effective enzyme candidates for most steps associated with each of the 
proposed pathways have been reported and/or characterized by others, or have 
appeared as part of our own previous works (Lin et al. 2014; Pugh et al. 2014; 
Thompson et al. 2016). Phenol-dependent MA biosynthesis (i.e. via pathways MA2-4) 
represents a new approach, however, and first required identification of a candidate 
gene whose expression would confer recombinant PH activity in E. coli.  PH activity 
has been identified as part of bacterial multicomponent monooxygenases (BMMs).  
BMMs represent a broad class of enzymes capable of using molecular oxygen to 
hydroxylate various hydrocarbon species, and have been identified to function in 
numerous microbes as the initial activating steps involved in degrading benzene, 
toluene, and xylene (Jindrová et al. 2002; Notomista et al. 2003; Sridevi et al. 2012).  
Notable examples include toluene/o-xylene monooxygenase (ToMo, encoded by 
touABCDEF) and phenol hydroxylase (PH, encoded by phKLMNOP), both from 
Pseudomonas stutzeri OX1, which together function to sequentially catalyze the first 
two steps in benzene degradation (i.e., via phenol then catechol) (Cafaro et al. 2004; 
Cafaro et al. 2002; Tinberg et al. 2011).  As promiscuous enzymes, previous in vitro 
studies have shown that both touABCDEF and phKLMNOP display the desired PH 
activity; however, phKLMNOP expectedly exhibits more favorable activity towards 
phenol (Km=0.6 μM, kcat=1.02 s-1), its native substrate, than does touABCDEF 
(Km=2.18 μM, kcat=1.00 s-1) (Cafaro et al. 2004).  Accordingly, phKLMNOP was 
selected as the initial candidate for establishing recombinant PH activity (step K; Figure 
3.1) in E. coli.  Meanwhile, whereas CDO activity (step C) has been identified in a 
variety of aromatic-degrading microorganisms (Bouwer and Zehnder 1993; Cao et al. 
2008; Kukor et al. 1988), CatA from P. putida displays high recombinant activity 
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(10.10 ± 0.35 μmol/min/mg protein) (Sun et al. 2013), and thus was accordingly used 
in each of MA1-5. 
 
Recombinant PH activity was confirmed in vivo via whole resting cell assays 
employing E. coli BW25113 pPh.  Because PH possesses carboxylate-bridged diiron 
catalytic centers in each of its N subunits, as well as a [2Fe-2S] cluster in the P subunit 
(Cafaro et al. 2004; Tinberg et al. 2011), the medium was first supplemented with 100 
μM Fe(NH4)2(SO4)2. Under these conditions, 1 mM exogenous phenol was rapidly 
0 1 2 3 8 12
0.00
0.25
0.50
0.75
1.00
 
 
Time (h)
0.00
0.25
0.50
0.75
1.00
B
 
 
 
M
e
ta
b
o
li
te
 (
m
M
)
A
Figure 3.3  Screening Candidate Phenol Hydroxylase ActivityEnzyme was assayed 
using whole resting cells with (dashed lines, open symbols) and without (solid lines, 
filled symbols) 100 μM Fe(NH4)2(SO4)2 supplementation.  A) Conversion of phenol 
(squares) to catechol (circles) by E. coli BW25113 pPh.  B) Conversion of phenol 
(squares) to catechol (circles) or muconic acid (diamonds) by E. coli BW25113 pPh-
CatA.  Error bars represent one standard deviation from triplicate experiments. 
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converted to catechol, achieving a maximum specific rate of 0.991 mmol g-1 h-1 (Figure 
3.3A).  However, after reaching a maximum level of 0.83 ± 0.04 mM after 40 min, 
catechol levels then gradually decreased over time, ultimately being undetected after 
8 h.  It was initially hypothesized that the disappearance of catechol was a result of 
dimer formation, as said phenomena have been reported to occur for various catechols 
in the presence of excess Fe(III) and under mildly acidic conditions, a process that 
plays an important role in adhesive formation in the mussel byssus (Fullenkamp et al. 
2014). To test this hypothesis, and determine if such an undesirable side reaction 
could perhaps be avoided, the assay was next repeated without Fe(NH4)2(SO4)2 
supplementation (Figure 3.3A).  Under these conditions, phenol conversion to catechol 
occurred at a similar yield (0.85 ± 0.03 mM catechol produced from 1 mM phenol after 
1.5 h), proceeding, however, at only ~60% of the previous maximum specific rate 
(just 0.596 mmol g-1 h-1).  However, even in the absence of Fe(III), catechol was again 
depleted following its formation, here completely disappearing after 12 h. As an 
alternative hypothesis, several BMMs have been reported to display promiscuous 
activity towards numerous, related aromatic species, including the repeated 
hydroxylation of the same initial substrate molecule (Tao et al. 2004; Vardar and Wood 
2005).  Thus, it was postulated that the PH encoded by phKLMNOP might also be 
capable of further hydroxylating catechol to 1,2,3-trihydroxybenzene (1,2,3-THB). LC-
MS analysis was performed on supernatants prepared from the above resting cell 
assays, wherein an unknown peak was identified with a molar mass (m/z) of 125.03 
± 0.02 (Figure B2, Appendix B).  As the molecular weight of 1,2,3-THB 126.11 g/mol, 
this strongly suggests that catechol disappearance is occurring due to its further 
hydroxylation to 1,2,3-THB by PH.  Although previously reported for ToMo (Vardar and 
Wood 2005), to the best of our knowledge, this is the first report of such behavior by 
phKLMNOP from P. stutzeri OX1.  
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Although it was determined that 1,2,3-THB is not inhibitory to E. coli (no 
significant growth defects observed in the presence of as much as 6 g/L 1,2,3-THB; 
Figure B3, Appendix B), for any pathway incorporating PH (i.e., MA2-4), co-production 
of 1,2,3-THB will likely compete for available catechol, thereby reducing MA 
production.  Accordingly, it was hypothesized that rapid turnover of catechol to MA by 
CDO might enable the undesirable production of 1,2,3-THB to be minimized upon 
implementation of the full pathway. As a preliminary test, the above experiment was 
repeated using whole resting cells of E. coli BW25113 pPh-CatA which co-express CDO 
(encoded by catA from P. putida KT2440) together with PH.  In this case, as seen in 
Figure 3B for both with and without Fe(NH4)2(SO4)2 supplementation, 1 mM phenol 
was converted to MA at maximum final concentrations of 0.62 ± 0.08 and 0.12 ± 0.01 
mM, respectively.  Thus, although co-expression of PH and CDO enabled the successful 
transformation of phenol to MA (which, unlike catechol, stably accumulated for the 
duration of the experiment; Figure 3.3B), overall conversion was low (reaching no 
greater than 62%) due to the persistent competing formation of 1,2,3-THB by PH.    
 
3.3.3. Investigating Phenol-Dependent Catechol Production in E. coli 
Three distinct phenol biosynthesis pathways (Thompson et al. 2016) were each 
next extended to catechol via the additional co-expression of phKLMNOP. This resulted 
in the construction of three novel catechol production pathways: CAT2 (steps J, K), 
CAT3 (steps G, H, I, K), and CAT4 (steps D, F, K) (Figure 3.1). When expressed in E. 
coli NST74 ∆pheA in shake flask cultures, phenol-dependent catechol biosynthesis 
from glucose was successfully demonstrated in all three cases, the results of which are 
compared in Table 3.3.  For each of CAT2-4, however, significant levels of residual 
phenol remained at the end of each culture (reaching as high as 149 ± 1 mg/L and, in 
all cases, surpassing total catechol production), suggesting low PH activity as a 
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common bottleneck.  In addition, similar to the whole resting cell assays, all three 
pathways further suffered from the competing formation of 1,2,3-THB, with detected 
levels reaching as much as 96 ± 4 mg/L. In the case of CAT2, catechol titers reached 
79 ± 3 mg/L at a glucose yield of 6.2 ± 0.28 mg/g. In addition to phenol, high levels 
of unconverted Tyr also accumulated in the medium, reaching 342 ± 12 mg/L after 96 
h, pointing to TPL as an additional flux limiting step in the pathway.  TPL, for example, 
is known to suffer from both equilibrium limitations (the reaction is reversible, with 
ΔrG'° = +27.9 kJ/mol; Figure 3.1) as well as feedback inhibition by phenol (e.g., 94 
mg/L phenol reduces TPL activity to only 23% of its maximum (Wierckx et al. 2008)).  
Among the three pathways, CAT3 enabled the highest catechol titer and yield, reaching 
100 ± 2 mg/L and 12.8 ± 0.26 mg/g, respectively; however, residual salicylate also 
accumulated at 55 ± 2 mg/L in this case.  Moreover, glucose utilization remained low 
among all strains, with overall consumption averaging just ~44% (Table 3.3), the 
precise reasons for which presently remain unclear. Thus, although functional and 
enabling phenol-dependent catechol production from glucose for the first time, all 
three novel catechol pathways (i.e., CAT2-4) suffer from inherent limitations 
associated with PH, both in terms of low recombinant activity as well as its apparent 
promiscuity. For comparison, the production of catechol via another, chorismate-
derived pathway, referred to here as CAT5 (steps D, E, B; Figure 3.1) (Pugh et al. 
2014) was investigated in parallel.  When expressed in the same host background and 
under identical culture conditions, said pathway enabled final catechol titers reaching 
up to 451 ± 44 mg/L at a glucose yield of 35.0 ± 3.0 mg/g – outputs 4.5- and 2.7-
fold greater, respectively, than those achieved by even CAT3 – and did so without 
significant terminal accumulation of any pathway intermediates.   
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Table 3.3  Catechol Production via Proposed Novel Pathways.  E. coli NST74 
∆pheA was used as the host background; results reflect 120h of culturing.  Error 
bars represent one standard deviation from triplicate experiment.   
aPugh et al. (2014). 
Pathway 
Accumulated 
Intermediate(s) 
(mg/L) 
Catechol 
(mg/L) 
Glucose 
Utilization 
(%) 
YP/S (mg/g) 
CAT2 
Tyr:  342 ± 12 
Phenol:  149 ± 1 
79 ± 3 65 ± 1 6.2 ± 0.28 
CAT3 
Salicylate:  55 ± 2 
Phenol:  111 ± 2 
100 ± 2 39 ± 1 12.8 ± 0.26 
CAT4 Phenol:  125 ± 9 51 ± 10 27 ± 1 9.4 ± 2.1 
CAT5a n.d. 451 ± 44 64 ± 1 35.0 ± 3.0 
 
3.3.4. Investigating MA Production via Newly Engineered Pathways 
The relative prospects of MA biosynthesis via the three phenol-dependent 
pathways (MA2-4) and the previously-reported, chorismate-derived catechol pathway 
(MA5) were investigated via the additional co-expression of catA from P. putida 
KT2440 (encoding CDO).  E. coli NST74 ∆pheA was again employed as the initial host 
background of interest, and the results are compared in Table 3.4. MA titers by MA2, 
which proceeds through phenol via Tyr, were lowest, reaching just 186 ± 11 mg/L at 
a glucose yield of 21.0 ± 2.2 mg/g.  As was the case for CAT2, this appears to be due 
at least in part to flux limitations associated with both TPL and PH, as indicated by the 
terminal accumulation of as much as 220 ± 12 mg/L Tyr and 63 ± 1 mg/L phenol.  
Like CAT3, MA3 resulted in the highest MA titers and yields among all phenol-derived 
pathways (i.e., MA2-4), reaching 484 ± 44 mg/L and 46.7 ± 6.0 mg/g, respectively. 
However, analogous to the case of catechol production, the common reliance upon PH 
in each of MA2-4 similarly resulted in production of 1,2,3-THB byproduct in each case, 
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here reaching as high as 232 ± 17 mg/L.  Furthermore, similar to CAT2-4, low glucose 
consumption was also observed for each of MA2-4, again averaging just 44% (Table 
3.4).  Meanwhile, perhaps expectedly, MA biosynthesis was highest in the case of MA5, 
reaching 819 ± 44 mg/L at a yield of 40.9 ± 2.2 mg/g.  Lastly, to provide a head-to-
head comparison, MA1 (i.e., the original ‘3DHS-derived’ pathway) was also 
constructed and expressed in the same host background.  In this case, MA production 
reached 1586 ± 11 mg/L at a yield of 79.3 ± 0.53 mg/g.  Overall, said results are 
consistent with the above model predictions that found MA1 to be the highest yield 
pathway (Figure 3.2). Interestingly, and in contrast to the original Draths and Frost 
study wherein an E. coli aroE background was used to promote 3DHS availability 
(resulting in multiple, undesirable auxotrophies), significant MA production via MA1 
was demonstrated here without disrupting the shikimic acid pathway.  This suggests 
that, at least under the present conditions, MA1 is capable of effectively competing 
against native metabolism for at least significant portion of available 3DHS. 
Furthermore, it should also be noted that although low PCA decarboxylase activity has 
been implicated as a limiting factor associated with MA production via MA1 (and here, 
by extension, perhaps also MA5) (Sonoki et al. 2014), as PCA remained undetected 
throughout any of the present cultures (Table 3.4), such effects do not appear to be 
limiting for the strains and conditions studied here. 
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Table 3.4  Novel Muconic Acid Production. E. coli NST74 ∆pheA was used as the 
host background; results reflect 120h of culturing.  Error bars represent one 
standard deviation from triplicate experiment. 
Pathway 
Accumulated 
Intermediate 
Metabolite 
(mg/L) 
MA 
(mg/L) 
Acetate 
(g/L) 
Glucose 
utilization 
(%) 
YP/S (mg/g) 
MA1 n.d. 1586 ± 11 12 ± 0.2 100 ± 1 79.3 ± 0.5 
MA2 
Tyrosine: 220 ± 12 
Phenol: 63 ± 1 
186 ± 11 10 ± 1 44 ± 4 21.0 ± 2.2 
MA3 n.d. 484 ± 44 7.1 ± 0.1 52 ± 2 46.7 ± 6.0 
MA4 n.d. 230 ± 20 7.1 ± 0.1 36 ± 1 31.8 ± 3.6 
MA5 n.d. 819 ± 44 12 ± 0.2 100 ± 1 40.9 ± 2.2 
 
 
3.3.5. Conclusions 
While MA production via three distinct and novel, phenol-dependent pathways 
was successfully demonstrated, the utility of said routes was ultimately limited by their 
common reliance on phenol hydroxylase – an enzyme with poor recombinant activity 
and high promiscuity.  Instead, chorismate-dependent production of catechol and 
ultimately MA by a novel pathway proceeding via p-hydroxybenzoate proved a more 
promising alternative, with titers reaching 819 ± 44 mg/L at a glucose yield of 40.9 ± 
2.2 mg/g.  Although this output lags significantly behind the original 3DHS-derived 
route, further strain engineering combined with dynamic synthetic flux regulation may 
ultimately result in higher achievable MA production metrics.     
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4. EXPLORING A SYNTHETIC METABOLIC FUNNELING APPROACH TO 
ENHANCE PHENOL AND MUCONIC ACID BIOSYNTHESIS 
 
Abstract 
 Phenol and muconic acid (MA) are industrially-relevant platform chemicals used 
for the synthesis of an array of plastics and polymers.  Multiple pathways for the 
renewable phenol and MA biosynthesis have previously been reported, each 
incorporating unique enzyme chemistries.  This unique flexibility with respect to 
pathway engineering arises in part because MA is also a common intermediate 
associated with the biodegradation of various aromatic compounds.  Further exploiting 
this principle, a synthetic ‘metabolic funnel’ was engineered wherein multiple distinct 
phenol and MA pathways stemming from different endogenous precursors were 
expressed in parallel to maximize net precursor assimilation and flux towards the final 
product.  Using this novel strategy, maximal phenol and MA titers exceeding 0.5 and 
3 g/L were realized, both representing the highest production metrics reported via any 
single pathway to date.  
 
Select portions of this chapter have been submitted as: 
Thompson, B., Pugh, S., Machas, M., Nielsen, D.R. Exploring Novel Pathways and 
Synthetic Metabolic Funneling to Enhance Muconic Acid Biosynthesis. Metab Eng 
(2017). 
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4.1. Introduction 
Phenol and muconic acid (MA) are important building block molecules used in 
the synthesis of various plastics and polymers of industrial relevance (Adkins et al. 
2012; Deng et al. 2016).  Although the complete biosynthesis of phenol and MA from 
glucose has previously been demonstrated, in both cases, the original engineered 
pathways suffer from notable inherent limitations.  Phenol, for example, was 
synthesized from endogenous tyrosine via expression of heterologous tyrosine phenol 
lyase (TPL) activity (Wierckx et al. 2008; Wierckx et al. 2005).  Although phenol was 
successfully synthesized with maximal shake flask titers reaching 141 mg/L (Wierckx 
et al. 2005), TPL reaction reversibility and enzymatic feedback inhibition ultimately 
resulted in poor pathway efficiency and limited production metrics (Kim et al. 2014; 
Wierckx et al. 2008).  As an alternative approach, two novel pathways were engineered 
and comparatively evaluated against the original tyrosine-derived pathway, both of 
which instead stem from endogenous chorismate (Thompson et al. 2016).  Using these 
pathways, titers reached as high as 377 mg/L, although overall yields via any phenol 
pathway remained less than 10% of the theoretical maximum (Thompson et al. 2016).  
Meanwhile, MA biosynthesis was originally constructed via a three-step pathway 
stemming from endogenous 3-dehydroshikimate (3DHS).  Although shake flask 
cultures resulted in the accumulation of 2.4 g/L MA (Draths and Frost 1994), high 
carbon flux to MA necessitated the creation of multiple nutrient auxotrophies resulting 
in expensive medium formulations and poor scalability.  As an alternative approach, 
numerous novel pathways to MA have been reported to date, all of which stem from 
endogenous shikimic acid pathway precursors downstream of 3DHS, importantly 
preserving chorismate biosynthesis and avoiding the creation of multiple nutrient 
auxotrophies (Curran et al. 2013; Johnson et al. 2016; Lin et al. 2014; Sengupta et 
al. 2015; Sun et al. 2013; Sun et al. 2014; Weber et al. 2012; Zhang et al. 2015a; 
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Zhang et al. 2015b).  However, production metrics by each novel route lag significantly 
behind those achieved via the 3DHS derived pathway.  
The unique flexibility by which phenol and MA can be synthesized via multiple 
different pathways arises in part because they are key intermediates involved in 
naturally-occurring aerobic degradation pathways used by various microbes to 
catabolize aromatic chemicals including, for example, those from plant biomasses (i.e. 
lignin-derived monomers) (Douglas 1996; Herrmann 1995; Sridevi et al. 2012) and 
petrochemicals (e.g. BTEX) (Jindrová et al. 2002) (Figure 4.1).  In addition, catechol, 
which serves as the ubiquitous MA precursor, is supplied to the β-ketoadipate pathway 
(which precedes and supplies substrates to the TCA cycle) from an array of different 
aromatic compounds, including phenol, via a series of so-called ‘funneling pathways’ 
(Bouwer and Zehnder 1993; Linger et al. 2014).  Drawing from and inspired by these 
natural mechanisms, the construction of a unique synthetic ‘metabolic funnel’ (Figure 
4.1) was investigated as a strategy capable of enhancing phenol and MA production 
via the parallel co-expression of distinct yet converging biosynthesis pathways.  As an 
analogous approach, β-carotene biosynthesis can be achieved via two disparate 
pathways: (i) an optimized mevalonate (MVA) pathway, and (ii) a hybrid 
methylerythritol phosphate (MEP) pathway (Pérez-Gil and Rodríguez-Concepción 
2013).  Through simultaneous co-expression of the MVA and MEP pathways, 
production metrics were increased by as much as 113-fold relative to the single 
pathway controls (Yang and Guo 2014).  Given these results, utilizing a synthetic 
‘funneling’ approach demonstrates how product titers and yields can be improved 
relative to single pathway controls. 
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4.2. Materials and Methods 
4.2.1. Strains and Media 
All strains used in this study are listed in Table 4.1.  E. coli NEB10-beta (New 
England Biolabs (NEB); Ipswich, MA) was used for all cloning and plasmid 
maintenance.  E. coli NST74 (ATCC 31884) was obtained from the American Type 
Culture Collection (ATCC; Manassas, VA) and served as the parent strain in this study.  
E. coli JW2580-1, JW1843-2, JW1666-3, and JW2410-1 were obtained from the Coli 
Figure 4.1  Engineering a Synthetic Metabolic ‘Funnel’This approach utilizes the 
simultaneous co-expression of two distinct muconic acid (MA) biosynthesis pathways, 
stemming from two different precursors (3DHS and chorismate), both derived from 
the shikimic acid pathway.  Also shown are the native mechanisms by which different 
aromatic degradation pathways also ‘funnel’ various substrates and intermediates 
towards MA, in this case for further metabolism via the β-ketoadipate pathway. Black 
bold dashed arrows represent multiple enzyme reactions native to E. coli; blue solid 
arrows represent individual enzyme steps associated with the pathways engineered in 
this chapter; gray solid and dashed arrows represent individual and multi-step enzyme 
processes associated with the aerobic degradation of aromatic chemicals.  PCA: 
protocatechuate; pHBA: p-hydroxybenzoate; AAA: aromatic amino acids; TCA: 
tricarboxylic acid cycle. 
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Genetic Stock Center (CGSC; New Haven, CT) and served as the genetic source for 
the pheA::KanR, pykA::KanR, pykF::KanR, and crr::KanR  cassettes, respectively.  E. 
coli BW25113 was obtained from the CGSC and served as the genetic source for ubiC 
and entC.  Citrobacter braakii (ATCC 29063) was obtained from the ATCC and served 
as the genetic source for tutA.  Klebsiella pneumoniae PZH572 (ATCC 25955) was 
obtained from the ATCC and served as the genetic source of kpdBCD and aroY.  
Pseudomonas aeruginosa PAO1 (DSMZ 22644) was obtained from the Leibniz Institute 
German Collection of Microorganisms and Cell Cultures and served as the genetic 
source of pobA.  Pseudomonas putida KT2440 (ATCC 47054) was obtained from the 
ATCC and served as the genetic source for catA.  Corynebacterium glutamicum (ATCC 
13032) was obtained from the ATCC and served as the genetic source of qsuB.   
Seed cultures of E. coli strains were cultured in Luria-Bertani (LB) broth at 32ºC 
and supplemented with 100 mg/L ampicillin, 35 mg/L kanamycin, and/or 34 mg/L 
chloramphenicol, as appropriate.  For phenol biosynthesis, shake flasks were cultured 
at 32ºC in MM1 phosphate limited minimal media supplemented with appropriate 
antibiotics.  MM1 was composed of the following (in g/L): MgSO4·7H2O (0.5), 
(NH4)2SO4 (4.0), MOPS (24.7), KH2PO4 (0.3), K2HPO4 (0.7), and glucose (20).  For MA 
biosynthesis, shake flasks were cultured at 32ºC in M9M minimal media supplemented 
with appropriate antibiotics.  M9M was composed of the following (in g/L): Na2HPO4 
(6), KH2PO4 (3), NaCl (0.5), NH4Cl (2), MgSO4·7H2O (0.493), CaCl2·2H2O (0.0147), 
and glucose (20).  Trace elements were supplemented in MM1 and M9M as follows (in 
mg/L): (NH4)6Mo7O24∙4H2O (0.37), H3BO3 (2.5), CoCl2∙6H2O (0.714), CuSO4 (0.16), 
MnCl2∙4H2O (1.6), ZnSO4∙7H2O (0.288), FeCl3 (0.05).   
 
  
69 
Table 4.1  Strains and Plasmids Used for Phenol and MA Production 
Strain Description Source 
E. coli NEB10-beta Δ(ara-leu) 7697 araD139  fhuA ΔlacX74 galK16 galE15 
e14- ϕ80dlacZΔM15 recA1 relA1 endA1 nupG 
rpsL (StrR) rph spoT1 Δ(mrr-hsdRMS-mcrBC)  
NEB 
E. coli BW25113 Source of ubiC and entC CGSC 
E. coli JW2580-1 Source of pheA::KanR CGSC 
E. coli JW1843-2 Source of pykA::KanR CGSC 
E. coli JW1666-3 Source of pykF::KanR CGSC 
E. coli JW2410-1 Source of crr::KanR CGSC 
E. coli NST74 aroH367, tyrR366, tna-2, lacY5, aroF394(fbr), malT384, 
pheA101(fbr), pheO352, aroG397(fbr) 
ATCC 
E. coli NST74 ∆pheA pheA chromosomal deletion in E. coli NST74 Pugh et al. 
(2014) 
E. coli NST74 ∆pheA 
∆pykA ∆pykF ∆crr 
crr chromosomal deletion in E. coli NST74 ∆pheA ∆pykA 
∆pykF 
This study 
C. glutamicum Source of qsuB ATCC 
C. braakii Source of tutA ATCC 
P. aeruginosa PAO1 Source of pobA and pchB DSMZ 
E. coli BW25113 Source of ubiC and entC CGSC 
K. pneumoniae PZH572 Source of kpdBCD and aroY ATCC 
P. putida KT2440 Source of catA ATCC 
Plasmid Description Source 
pTrc99A pBR322 ori, Ampr, lacIq, Ptrc Prather Lab, MIT 
pTrcCOLAK ColA ori, Kanr, lacIq, Ptrc McKenna et al. 
(2013) 
pY3 p15A, Ampr, lacI, Plac-UV5-tyrB-tyrAfbr-aroC T1-Ptrc-aroA-
aroL 
Juminaga et al. 
(2012) 
pS3 pBBR1 ori; Cmr, lacI Plac-UV5-aroE-aroD-aroBop-aroGfbr-
ppsA-tktA 
Juminaga et al. 
(2012) 
pKD46 repA101(ts) and R101 ori, Ampr, araC, araBp CGSC 
pCP20 FLP, ts-rep, [cI857](lambda)(ts), Ampr CGSC 
pTyrAfbr-TutA tyrAfbr of E. coli and tutA of C. braakii inserted to pY3 
backbone 
This study 
pSDC-PchB-EntC SDC of T. moniliforme, pchB of P. aeruginosa PAO1, and 
entC of E. coli BW25113 inserted to pS3 backbone 
This study 
pUbiC-Kpd ubiC of E. coli and kpdBCD of K. pneumoniae PZH572 
inserted to pTrcCOLAK 
Thompson et al. 
(2015) 
pUbiC-PobA ubiC of E. coli BW25113 and pobA of P. aeruginosa PAO1 
inserted to pTrc99A 
Pugh et al. 
(2014) 
pAroY aroY of K. pneumoniae PHZ572 inserted to pTrcCOLAK Pugh et al. 
(2014) 
pAroY-CatA catA of P. putida KT2440 inserted to pQsuB-AroY This study 
pQsuB-AroY qsuB of C. glutamicum and aroY of K. pneumoniae 
PHZ572 inserted to pS3 backbone 
This study 
pQsuB-AroY-CatA catA of P. putida KT2440 inserted to pQsuB-AroY This study 
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Table 4.2  Strains Engineered for Phenol and MA Metabolic ‘Funneling’ 
Pathway Plasmid Combination Source 
PH1 pTyrAfbr-TutA,  This study 
PH2 pSDC-PchB-EntC This study 
PH3 pUbiC-Kpd This study 
PHF1 pTyrAfbr-TutA, pSDC-PchB-EntC This study 
PHF2 pTyrAfbr-TutA, pUbiC-Kpd This study 
PHF3 pSDC-PchB-EntC, pUbiC-Kpd This study 
PHF4 pTyrAfbr-TutA, pSDC-PchB-EntC, pUbiC-Kpd This study 
MA1 pQsuB-AroY-CatA This study 
MA5 pUbiC-PobA, pAroY-CatA This study 
MAF pUbiC-PobA, pQsuB-AroY-CatA This study 
 
4.2.2. Plasmid Construction 
All plasmids used and developed in this study are listed in Table 4.1. All genes 
were PCR amplified with Q5 High-Fidelity DNA Polymerase (NEB) and a BioRad iCycler, 
per manufacturer protocols.  Custom DNA oligonucleotide primers (See Table C1, 
Appendix C) were synthesized by Integrated DNA Technologies (IDT, Coralville IA).  
Genomic DNA (gDNA) templates were prepared using the ZR Fungal/Bacterial DNA 
MiniPrep kit while plasmid DNA was purified using the Zymo Plasmid MiniPrep kit (both 
Zymo Research, Irvine CA).  Amplified linear DNA fragments were purified using the 
Zymo DNA Clean & Concentrator MiniPrep kit (Zymo Research).  Select purified linear 
and plasmid DNA were digested using appropriate restriction endonucleases (NEB) and 
subsequently gel purified using the Zymoclean Gel DNA Recovery MiniPrep kit (Zymo 
Research).  Purified digested DNA fragments were ligated using T4 DNA Ligase (NEB), 
per manufacturer protocols.  Alternatively, purified linear DNA was subsequently used 
as template DNA for either circular polymerase extension cloning (CPEC) (Quan and 
Tian 2011) with Q5 High-Fidelity DNA Polymerase according to manufacturer protocols, 
or Gibson Assembly (Gibson 2009; Gibson et al. 2009) using Gibson Assembly Master 
Mix (NEB) according to manufacturer protocols.  Ligation, CPEC, and Gibson Assembly 
reactions were transformed into chemically competent E. coli NEB10-beta before 
plating on LB solid agar media supplemented with appropriate antibiotics for selection.  
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Transformant pools were screened using colony PCR, restriction digest mapping, and 
finally confirmed by DNA sequencing.  
 
4.2.3. Strain Construction 
All strains engineered and used in this study are listed in Table 4.2.  
Chromosomal in-frame deletions of pheA in E. coli NST74 was constructed using a 
modified version of the Datsenko and Wanner method (Datsenko and Wanner 2000), 
as previously described (Pugh et al. 2014).  The pheA::FRT-kanR-FRT, pykA::FRT-
kanR-FRT, pykF::FRT-kanR-FRT, and crr::FRT-kanR-FRT deletion cassettes were PCR 
amplified from E. coli JW2580-1, JW1843-2, JW1666-3, and JW2410-1, respectfully.  
Chromosomal integration of said cassette and subsequent removal of kanR marker was 
achieved as previously described (Datsenko and Wanner 2000; Pugh et al. 2014), 
resulting in the individual construction of E. coli NST74 ∆pheA and E. coli NST74 ∆pheA 
∆pykA ∆pykF ∆crr. 
For phenol, catechol, and MA biosynthesis, E. coli NST74 ∆pheA and E. coli 
NST74 ∆pheA ∆pykA ∆pykF ∆crr were co-transformed with the following combinations 
of plasmids (note: pathway designation provided in parentheses, see Table 4.2): 
pTyrAfbr-TutA (PH1), pSDC-PchB-EntC (PH2), pUbiC-Kpd (PH3), pTyrAfbr-TutA and 
pSDC-PchB-EntC (PHF1), pTyrAfbr-TutA and pUbiC-Kpd (PHF2), pSDC-PchB-EntC and 
pUbiC-Kpd (PHF3), pTyrAfbr-TutA and pSDC-PchB-EntC and pUbiC-Kpd (PHF4),  
pQsuB-AroY-CatA (MA1), pUbiC-PobA and pAroY-CatA (MA5), and pUbiC-PobA and 
pQsuB-AroY-CatA (MAF). 
 
4.2.4. Phenol and MA Production 
To investigate the bioproduction of phenol and MA, overnight seed cultures 
were first prepared in LB and supplemented with 100 mg/L ampicillin, 35 mg/L 
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kanamycin, and/or 34 mg/L chloramphenicol and used to inoculate (1% vol) 50 mL of 
MM1 (phenol) or M9M (MA) minimal media supplemented with 20 g/L glucose in 250 
mL shake flasks (note: the medium was additionally supplemented with 0.1 g/L Phe 
when using ∆pheA-derived host strains). Shake flask cultures were incubated at 32ºC 
with shaking at 200 RPM until reaching OD600 ~0.7, at which point IPTG induction was 
performed at a final concentration of 0.4 mM. Cultures were further incubated for a 
total of up to 120 h, or until significant sugar consumption was no longer detected.  
Periodically, samples were drawn to measure cell growth (as OD600) as well as sugar 
and metabolite levels by HPLC analysis, as described below.  Prior to centrifugation, 
samples for MA analysis were first diluted 1:10 with methanol, while samples for Tyr 
analysis were diluted 1:10 with 1 N HCl and incubated at 55°C for 30 min.  All samples 
were then centrifuged at 11,000 x g for 5 min before transferring the supernatant to 
a glass HPLC vial. 
 
4.2.5. HPLC Metabolite Analysis 
Metabolite analysis was performed using a Hewlett Packard 1100 series HPLC 
system.  Separation of Phe, pHBA, PCA, salicylate, phenol, catechol, and MA, was 
achieved using a reverse-phase Hypersil GOLD aQ C18 column (3 mm x 250 mm; 
Thermo Fisher, Waltham, MA, USA) operated at 45°C with an isocratic 0.8 mL/min 
mobile phase consisting of 85% (vol.) 5 mM H2SO4 and 15% (vol.) acetonitrile.  The 
eluent was monitored using a diode array detector (DAD) set at 215 nm for Phe, 
salicylate, PCA, and catechol, 260 nm for pHBA, and 275 nm for phenol and MA.  
Separation of Tyr was also achieved on the same Hypersil GOLD aQ C18 column, in 
this case maintained at 30°C while using a mobile phase consisting of water (A) and 
methanol plus 0.1% (vol.) formic acid (B) at a constant flow rate of 0.2 mL/min and 
the following concentration gradient (all by vol.): 5% B from 0 to 8 min, 5% to 40% 
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B from 8 to 13 min, 40% B from 13 to 16 min, 40 to 5% B from 16 to 21 min, and 5% 
B from 21 to 31 min.  The eluent was monitored using a DAD at 215 nm.  Glucose and 
acetate separation was achieved using an Aminex HPX-87H column (BioRAD, Hercules, 
CA) operated at 35ºC and detected using a refractive index detector (RID).  The 
column was eluted with 5 mM H2SO4 at a constant flow rate of 0.55 mL/min. In all 
cases, external standards were prepared and used to provide calibrations for 
concentration determination. 
 
4.3. Results and Discussion 
4.3.1. Demonstrating Phenol and MA Production via Synthetic ‘Metabolic 
Funneling’ 
To avoid the inherent limitations associated with the original phenol and MA 
biosynthesis routes, a synthetic ‘metabolic funneling’ approach was investigated as a 
novel strategy for further improving production metrics.  In the case of phenol, 
multiple ‘funneling’ strategies were investigated by co-expressing both the original 
tyrosine-derived pathway (PH1, Figure 4.2) with the salicylate derived pathway (PH2, 
Figure 4.2) and/or the p-hydroxybenzoate (pHBA) derived pathway (PH3, Figure 4.2).  
In this way, phenol production occurs via either two or three simultaneous and 
compatible routes (Table 4.3).  As with the novel phenol pathways, the ‘funneling’ 
derived strains were first introduced and expressed in E. coli NST74 ∆pheA.  In the 
case of PHF1, titers reached 439 ± 7 mg/L at a glucose yield of 24.0 ± 0.51 mg/g, 
representing a 16% increase in titer over the best single pathway control, although 
the yield decreased by 33%.  In the case of PHF2, titers reached 355 ± 17 mg/L at a 
glucose yield of 17.8 ± 1.2 mg/g.  Meanwhile, phenol titers by PHF3 reached just 149 
± 10 mg/L at a glucose yield of 8.4 ± 1.0 mg/g.  Finally, with all three pathways 
expressed simultaneously (PHF4), phenol titers reached 205 ± 13 mg/L at a glucose 
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yield of 11.8 ± 0.72 mg/g.  While titers by PHF1 represent a modest increase over the 
single pathway controls, production metrics achieved by PHF2, PHF3, and PHF4 all 
represent an overall decrease relative to their single pathway controls.  Although the 
exact mechanism(s) for the observed decrease remain unclear, significant acetate 
accumulation was observed in all cases (Table 4.3) suggesting high rates of glucose 
consumption and significant overflow metabolism.    
Meanwhile, to further improve upon the high production potential of the original 
3DHS-derived route, a synthetic ‘funneling’ pathway (MAF) was engineered by co-
expressing both the original pathway (MA1, Figure 4.1) and the second, best-
performing chorismate-derived pathway (MA5, Figure 4.1), the latter of which provides 
Sugar
Chorismate
Tyrosine Salicylate pHBA
Phenol
PH1 PH2 PH3
Figure 4.2  Engineering a Synthetic Funnel for Phenol Production.  
Enhanced biosynthesis can be achieved via the simultaneous co-
expression of two or three distinct pathways, all stemming from 
chorismate as the common endogenous shikimic acid pathway 
precursor.  Black bold dashed arrow represents multiple enzyme 
reactions native to E. coli; blue solid arrows represent individual 
enzyme steps associated with the pathways engineered in this chapter; 
pHBA: p-hydroxybenzoate. 
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an opportunity to ‘rescue’ additional endogenous precursors not initially ‘captured’ at 
the first branch point (i.e., at 3DHS).  In addition, this concept importantly avoids the 
need for multiple nutrient auxotrophies as required for significant production via MA1.  
As with the phenol and individual MA pathways, MAF was first introduced and 
expressed in E. coli NST74 ∆pheA, resulting in the accumulation of 2042 ± 88 mg/L 
MA at a glucose yield of 102 ± 4.4 mg/g (Table 4.3).  When compared to MA1, this 
suggests that as much as an additional 456 mg/L MA (22% of total MA) was produced 
via the ability of the ‘lower branch’ (i.e., MA5) to assimilate precursors (in this case, 
chorismate) not initially taken in via the ‘upper branch’ (i.e., MA1).  Overall, when 
compared to strains expressing the single, parent pathways (i.e., MA1 or MA5 alone), 
the combined ‘funneling’ strategy of MAF resulted in MA titer improvements of 29 and 
150%, respectively, and 29 and 132% in terms of achievable yields.  However, similar 
to the phenol production, significant acetate accumulation was observed (Table 4.3), 
again suggesting high rates of glucose uptake and overflow metabolism.  
 
Table 4.3  Evaluating Metabolic ‘Funneling’ for Phenol and MA Biosynthesis.  The 
use of synthetic ‘metabolic funneling’ for improving production was investigated 
using E. coli NST74 ∆pheA as the host background.  Strains were cultured for 
120h.  Error represents one standard deviation from triplicate experiments.  MA: 
Muconic acid.  
Pathway Product (mg/L) 
Glucose 
Utilization (%) 
Acetate 
(g/L) YP/S (mg/g) 
PH1 Phenol: 377 ± 23 100 ± 1 9 ± 0.1 18.7 ± 0.72 
PH2 Phenol: 377 ± 14 53 ± 0.7 6 ± 0.3 35.7 ± 0.80 
PH3 Phenol: 149 ± 12 100 ± 1 4 ± 0.3 7.3 ± 0.31 
PHF1 Phenol: 439 ± 7 90 ± 0.9 8 ± 0.2 24.0 ± 0.51 
PHF2 Phenol: 355 ± 17 100 ± 1 6 ± 0.2 17.8 ± 1.2 
PHF3 Phenol: 149 ± 10 90 ± 0.4 6 ± 0.3 8.4 ± 1.0 
PHF4 Phenol: 205 ± 13  87 ± 0.3 5 ± 0.2 11.8 ± 0.72 
MA1 MA: 1586 ± 11 100 ± 1 12 ± 0.2 79.3 ± 0.53 
MA5 MA: 819 ± 44 100 ± 1 12 ± 0.2 40.9 ± 2.2 
MAF MA: 2042 ± 88 100 ± 1 11 ± 0.2 102 ± 4.4 
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4.3.2. Host Engineering to Enhance Precursor Availability  
To further improve phenol and MA production, subsequent strain engineering 
efforts were focused on increasing total carbon flux into the shikimic acid pathway and 
reducing overflow metabolism observed with high glucose uptake rates (Liu et al. 
2014).  Flux into the shikimic acid pathway is initially controlled by 3-deoxy D-
arabinoheptulose 7-phosphate (DAHP) synthase, whose two substrates are 
phosphoenolpyruvate (PEP) and erythrose 4-phosphate (E4P) (Bongaerts et al. 2001; 
Gosset 2009; Rodriguez et al. 2014).  As previously demonstrated (Gosset 2005; 
Postma et al. 1993), increasing the intracellular availability of PEP is an effective 
strategy for enhancing the production of aromatic amino acids (Liu et al. 2014) and 
other products from intermediates of the shikimic acid pathway (Noda et al. 2016).  In 
glucose-fed cultures, PEP availability can be increased by blocking its conversion to 
pyruvate via deletion of pykA and pykF, both of which encode isozymes of pyruvate 
kinase.  Meanwhile, rapid uptake of glucose has been previously reported to result in 
the accumulation of acetate (Gosset 2005) – an undesirable byproduct which can 
ultimately inhibit cell metabolism (Shiloach et al. 1996) and result in lower aromatic 
product yields (Liu et al. 2014).   As seen in Table 4.3, significant levels of residual 
acetate were observed with phenol and MA production, with levels reaching as high as 
12 g/L.  Carbohydrate repression resistant null mutants (i.e., crr) have been 
previously shown to display lower rates of glucose uptake and thus reduced overflow 
metabolism – a strategy demonstrated as effective for enhancing phenylalanine 
production (Liu et al. 2014).  Accordingly, E coli NST74 ∆pheA ∆pykA ∆pykF ∆crr was 
next constructed and evaluated as a phenol and MA production host.   
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Table 4.4  Comparing Engineering Strategies for Phenol and MA Production.  
The use of synthetic ‘metabolic funneling’ for improving production was 
investigated using E. coli NST74 ∆pheA ∆pykA ∆pykF ∆crr as the host 
background.  Strains were cultured for 120h and consumed 20 g/L glucose.  
Error represents one standard deviation from triplicate experiments. 
 
Pathway 
Phenol 
(mg/L) 
Glucose 
Utilization (%) 
Acetate 
(g/L) YP/S (mg/g) 
PH1 329 ± 9 100 ± 1 6 ± 0.1 16.4 ± 0.65 
PH2 277 ± 15 100 ± 1 7 ± 0.1 13.8 ± 0.19 
PHF1 575 ± 19 100 ± 1 5 ± 0.3 28.8 ± 0.34 
MA1 1792 ± 28 100 ± 1 n.d. 89.6 ± 1.4 
MAF 3153 ± 149 100 ± 1 7 ± 0.1 158 ± 7.4 
 
In the case of phenol, the pathway focus narrowed to the best performing 
pathways: PH1, PH3, and PHF1.  The individual pathways PH1 and PH3 displayed a 
modest decrease in titer and yield when using E coli NST74 ∆pheA ∆pykA ∆pykF ∆crr 
as host, with final phenol titers reaching 329 ± 9 and 277 ± 15 mg/L, respectively.    
On the other hand, phenol production by PHF1 was slightly enhanced, with final titers 
reaching 575 ± 19 at a glucose yield of 28.8 ± 0.34 – a 1.3 and 1.2-fold increase 
relative to the previous generation strain.  In addition, the titer demonstrated by the 
novel ‘metabolic funneling’ pathway represents a 4-fold increase over the original 
phenol biosynthesis reported using the solvent tolerant P. putida (Wierckx et al. 2005) 
and a 1.4-fold increase over the highest E. coli derived phenol production reported to 
date (Kim et al. 2014).  In both cases, acetate accumulation was reduced relative to 
the same pathways used in E coli NST74 ∆pheA, although significant levels remained 
at the end of culturing (as much as 6 g/L, Table 4.4).  Both engineered pathways each 
result in the generation of 1 additional pyruvate via TPL (PH1, step J, Figure 3.1) and 
chorismate pyruvate lyase (encoded by pchB, PH2, step H, Figure 3.1) activities.  While 
future works will be required to test this hypothesis, it is possible that said pyruvate 
is then converted to acetyl-CoA and ultimately to acetate via E. coli’s phosphate 
acetyltransferase and acetate/acetyl-CoA pathway (encoded by pta-ackA), providing 
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the cell with 1 ATP in the process.  Further host engineering to incorporate additional 
mutations previously reported as effective for reducing acetate accumulation during 
aromatic amino acid biosynthesis will also be investigated (Castaño-Cerezo et al. 
2009; Liu et al. 2016; Wang et al. 2013; Wolfe 2005) with the goal of further improving 
phenol production.  
Meanwhile, in the case of MA, the pathway focus narrowed to just MA1 and 
MAF: the two most promising pathways.  As seen in Table 4.4, acetate accumulation 
was effectively eliminated in the case of MA1, while the additional mutations enabled 
a modest (~13%) increase in MA production with final titers reaching 1792 ± 28 mg/L 
at a glucose yield of 89.6 ± 1.4 mg/g. On the other hand, MA production by MAF was 
significantly enhanced using E coli NST74 ∆pheA ∆pykA ∆pykF ∆crr as host, with final 
MA titers reaching 3153 ± 149 mg/L at a glucose yield of 158 ± 7.4 mg/g – both 
increase of over 1.5-fold increase relative to the use of E coli NST74 ∆pheA as host, 
and the highest production metrics achieved in this study.  Furthermore, this maximal 
titer also is 31% higher than the 2.4 g/L of MA reported by Draths and Frost via MA1 
in an E. coli aroE background (Draths and Frost 1994), and was notably achieved 
while generating only a single auxotrophy (i.e., for Phe).  Further comparing the results 
of Tables 4.3 and 4.4, although the apparent flux of precursor through the ‘upper 
branch’ (i.e., MA1) was only slightly improved, the ‘lower branch’ (i.e., MA5) appeared 
to offer an even greater benefit, in this case enabling the production of as much as an 
additional 1361 mg/L MA (43% of total MA produced).  The additional ∆pykA, ∆pykF, 
and ∆crr mutations appear to have more greatly improved the intracellular availability 
of chorismate than that of 3DHS.  Interestingly, acetate accumulation reemerged with 
MAF, reaching up to 7 ± 0.1 g/L by the end of the culture (Table 4.4).  Unlike MA1, 
the first step of MA5 (step D, Figure 3.1) is catalyzed by chorismate pyruvate lyase 
(encoded by native ubiC) and results in the generation of 1 pyruvate molecule, which, 
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similar to the phenol results, may ultimately be converted to acetate.  The same host 
engineering and additional mutations previously discussed could similarly be 
investigated with the goal of reducing acetate accumulation and improving MA 
production via MAF.  
 
4.3.3. Synthetic ‘Funneling’ for Renewable Chemical Production 
Two novel ‘metabolic funneling’ pathways were constructed for the complete 
biosynthesis of phenol and MA from glucose, resulting in titers reaching 0.58 and 3.1 
g/L, respectively.  In both cases, additional strain engineering to reduce unwanted 
acetate accumulation may ultimately lead to higher achievable production metrics.  
Whereas product toxicity is a common concern with the production of aromatic 
chemicals (McKenna and Nielsen 2011; McKenna et al. 2013), further increases in 
phenol production may ultimately reach a toxic threshold (estimated at 1.8 g/L in rich 
media (Kim et al. 2014)).  Others have demonstrated that in situ product removal can 
effectively improve overall phenol biosynthesis (Miao et al. 2015b); such an approach 
may prove analogously helpful with the phenol ‘funneling’ pathway combination.   
Although many products of interest have only one heterologous pathway 
reported to date, one interesting prospect for future works is the biosynthesis of 3-
hydroxypropionate (3HP).  3HP is a versatile platform chemical used for the production 
of polymers, acrylates, and lubricants (Kumar et al. 2013).  To date, no fewer than 
seven novel routes have been proposed, all of which ultimately stem from either 
pyruvate or PEP (Table 4.5).  Of the seven proposed pathways, only three (Pathways 
2, 3, and 6, Table 4.5) are reported to be energetically favorable, with either a 0 or 
+1 net ATP yield per mol of 3HP produced (Kumar et al. 2013).  Given these three 
favorable pathways, all combinations could be investigated for enhanced 3HP 
production using a synthetic ‘funneling’ strategy. Furthermore, an interesting 
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alternative approach would be to investigate the simultaneous co-expression of at least 
one energetically favorable pathway in parallel with at least one unfavorable pathway.  
More specifically, Pathway 6 is energetically favorable with a net ATP yield per mol 
3HP of +1 and has been demonstrated to result in the highest achievable titer and 
yield reported to date (Henry et al. 2010; Jiang et al. 2009).  Meanwhile, Pathway 4 
has a net ATP yield per mol 3HP of -1 and has been demonstrated as functional, 
although 3HP was produced at low levels (Liao et al. 2007).  Future works could 
investigate metabolic ‘funneling’ as a strategy for balancing pathway energetics, in the 
case utilizing the extra ATP produced via Pathway 6 to supplement the deficiency 
created via Pathway 4. 
 
Table4.5  3-hydroxypropionate Biosynthesis Pathways.  Net ATP is dependent on 
endogenous substrate and enzyme selection.  aKumar et al. 2013 
Pathway Intermediates 
Net ATP  
(mol / mol 3HP)a 
1 Pyruvate → Lacate → Lactoyl-CoA → Acryloyl-CoA → 3HP-CoA → 3HP 1/0 
2 Pyruvate → Acetyl-CoA → Malonyl-CoA → 3-oxopropanoate → 3HP 0 
3 Pyruvate/PEP → OAA → Aspartate → β-alanine → 3-oxopropanoate → 
3HP 
1/0 
4 Pyruvate/PEP → OAA → Aspartate → β-alanine → β-alanyl-CoA → 
Acryloyl-CoA → 3HP-CoA → 3HP 
0/-1 
5 Pyruvate/PEP → Succinate → Propionate/Propionyl-CoA → Acryloyl-
CoA → 3HP-CoA → 3HP 
-1/-0.33 
6 Pyruvate → α-alanine → β-alanine → 3-oxopropanoate → 3HP 1 
7 Pyruvate → α-alanine → β-alanine → β-alanyl-CoA → Acryloyl-CoA → 
3HP-CoA → 3HP 
1/0 
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4.4. Conclusions 
A synthetic ‘funneling’ approach was investigated to increase phenol and MA 
production while avoiding the inherent limitations associated with each original 
biosynthesis route.  In the case of phenol, co-expression of two phenol pathways in 
parallel enabled titers exceeding 0.5 g/L in shake flask cultures.  Meanwhile, co-
expression of two MA pathways in parallel resulted in a novel ‘funneling’ pathway 
enabled MA production at titers >3 g/L in shake flask cultures.  Utilizing said approach 
is expected to have broad applications metabolic engineering for improving the 
biosynthesis of an array of products of interest. 
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5. DISCUSSION AND FUTURE WORK 
 
Abstract 
 Novel phenol and muconic acid biosynthesis pathways have successfully been 
engineered to overcome inherent limitations associated with the original biosynthesis 
routes. Despite these novel contributions, significant room for improvement remains 
to further increase production metrics. This chapter discusses potential future work to 
further increase phenol and muconic acid production by characterizing and utilizing 
various dynamic flux control strategies with the potential to greatly increase 
availability of the relevant pathway precursors. 
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5.1. Engineering a Dynamic Phenotype Switch 
Through the rational design and engineering of natural and non-natural 
metabolic pathways, E. coli can serve as an efficient biocatalyst for the transformation 
of renewable sugars to various bulk and fine chemicals (Carothers et al. 2009; Curran 
and Alper 2012; Lee et al. 2011; Martin et al. 2009; Xie et al. 2006). Although 
developments in metabolic engineering and synthetic biology continue to expand an 
ever-growing library of heterologous pathway ‘parts’, there remains significant room 
for improvement regarding overall pathway performance. More specifically, in addition 
to producing the targeted end-product of interest, undesirable competing metabolic 
flux toward biomass and essential nutrients production remains a significant drain for 
available carbon resources (Figure 5.1) (Mao et al. 2009; Weikert et al. 1998; 
Youngquist et al. 2013).  Despite the identification of various native flux control 
mechanisms, including conditional promoter induction, riboswitches, attenuation 
mechanisms, and feedback regulation, these strategies are difficult to predict and 
therefore remain challenging to engineer. 
Whereas maximum product yields are achieved when competing metabolic flux 
is minimized, the engineering of static and dynamic control mechanisms to efficiently 
regulate both engineered and competing pathway flux is essential for increasing 
production metrics (Mao et al. 2009; Weikert et al. 1998; Youngquist et al. 2013).  
Static mechanisms include modulating gene expression levels through the rational 
adjustment of RBS strength, promoter strength, promoter induction level, and plasmid 
copy number.  While these techniques offer fine-tunable control of gene expression, 
they offer minimal impact with respect to restricting undesirable carbon loss to 
competing pathways.  In contrast, gene deletions eliminate carbon loss to competing 
metabolic networks, although this strategy is limited to either non- or only 
conditionally-essential genes. Whereas the former may have no discernable 
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phenotypic impact, the latter typically requires additional media supplements to 
support cell viability resulting in reduced host fitness and poor scalability.   
In contrast to the above mentioned, static strategies, competing pathway flux 
and undesired carbon loss can be minimized by engineering dynamic control 
strategies, resulting in more tractable and higher efficiency production platforms.  For 
example, sRNA has been used in pathway engineering to target non-essential genes 
as part of enhanced tyrosine and cadaverine biosynthesis (Na et al. 2013). Meanwhile, 
a metabolic toggle switch variant was previously demonstrated to effectively modulate 
flux between growth essential pathways and the production of 3-hydroxypropionic acid 
(Tsuruno et al. 2015). Moreover, by constructing a controllable native protein 
degradation system, myo-inositol production was enhanced by modulating the key 
glycolytic enzyme Pfk-I (Brockman and Prather 2015).  Finally, although dynamic 
chromosomal deletions have been modeled in silico, this approach has yet to be 
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Figure 5.1  Metabolic Flux Distribution for Enhanced Product Biosynthesis 
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demonstrated for pathway engineering (Gu et al. 2012).  Despite the successful 
implementation of these techniques, a head-to-head evaluation clearly identifying the 
relative merits and pitfalls associated with each strategy has not been performed.  
Furthermore, said strategies have typically been applied for the enhanced biosynthesis 
of one product with no further application to disparate pathways and products, 
resulting in underutilized techniques and a general ambiguity regarding their efficacy.   
The overall goal of future work to research presented here is to engineer, 
characterize, and comparatively evaluate five unique mechanisms, and combinations 
thereof, for creating a dynamic phenotype switch. These mechanisms will target 
transcriptional, translational, and post-translational control to achieve the desired 
dynamic phenotype switch.  GFP will serve as an initial model while the relative and 
absolute performance of each design can be compared. In all cases, the ideal control 
system will result in rapid loss of GFP expression (i.e., minutes vs. hours) and 
Time
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Dynamic control 
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Figure 5.2  Dynamic Flux Control Response. Flux control 
mechanisms can be evaluated using GFP  as a model system.  
Various GFP expression repression techniques can be investigated. 
The ideal outcome (solid line) will result in the rapid repression of 
GFP expression relative to the control (dashed line).  
86 
subsequent depletion of detectable GFP levels (Figure 5.2).  Each approach proposed 
for a dynamic phenotype switch has its own inherent advantages and disadvantages 
(Table 5.1), as will be discussed in greater detail in the following sections.  Overall, 
the most effective control system design may require simultaneous deployment of 
multiple mechanisms considered (e.g., CRISPRi in conjunction with targeted protein 
degradation) to ultimately realize both rapid and efficient phenotypic switching. The 
individual mechanisms of interest, as well as relevant factors to be considered with 
respect to their implementation and design, are discussed in the subsequent sections.    
 
Table 5.1  Dynamic Phenotype Control Mechanisms. Engineered approaches to be 
investigated each have unique advantanges and disadvantages.  
Dynamic Approach  Advantages Disadvantages 
CRISPRi • Targets DNA (single copy) 
• Multiple gene targets simultaneously 
• Two-part system 
• Off-target effects 
• Requires expression of 
heterologous deactivated 
protease 
• Residual protein 
Metabolic toggle 
switch 
• Tunable control between growth and 
product formation 
• Reversible 
 
• Large construct to implement 
• Inherently leaky expression 
• Reversible 
Dynamic chromosomal 
deletion 
• Irreversible 
 
• Requires chromosomal 
replacement 
• Difficult to fine tune 
• Irreversible 
sRNA • No host engineering 
• Small construct (~ 300 bp per 
target) 
• Multiple gene targets simultaneously 
• No additional protein expression 
required 
• Targets mRNA (multiple copies) 
• Off-target effects 
• Requires fine tuning for adequate 
repression 
• Residual protein 
Protein degradation • Fast degradation 
• No residual protein 
• Specific protein tag required 
• Require expression of exogenous 
or tuning of endogenous protease 
• Not all proteins degradable 
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5.1.1. Transcriptional Control 
To achieve the ideal control system, the use of transcriptional control will first 
be investigated via the clustered regularly interspaced short palindromic repeats 
(CRISPR) system: a system that has emerged as a powerful tool for a variety of 
applications, including gene editing and gene silencing (Jiang et al. 2015). In nature, 
these systems typically operate as a defense mechanism to cleave non-native DNA.  
CRISPR systems are comprised of two essential components: (a) a small guide RNA 
(sgRNA) and (b) the Cas9 protein.  The sgRNA consists of a base pairing region, a 
Cas9 handle, and a terminator, and is responsible for pairing to a specific DNA locus 
complimentary to the base pairing region. Once bound to the DNA locus, the Cas9 
protein cleaves the double strand DNA.  However, a deactivated Cas9 protein (dCas9) 
protein is catalytically inactive and does not exhibit endonuclease activity (Hawkins et 
al. 2015). Once bound to the DNA locus, the sgRNA-dCas9 complex precludes RNA 
polymerase binding, thereby disrupting gene transcription.  Notable advantages of this 
technique include the transcriptional repression of multiple gene targets 
simultaneously, whereas disadvantages include off-target effects and the requirement 
of an additional heterologous protease (Table 5.1).  To investigate this approach, a 
synthetic CRISPRi system will be constructed capable of modulating GFP transcription 
levels (Figure 5.3).  As an initial test platform, a custom designed CRISPRi system 
(Figure 5.3A), composed of a custom synthesized sgRNA and dCas9, will be used for 
transcriptional repression of GFP (Figure 5.3B).  GFP expression levels over time will 
be evaluated to fully characterize the inducible CRISPRi system. 
The second transcriptional control approach will investigate the use of a 
metabolic toggle switch.  One prospective toggle switch design relies on a dual 
promoter-repressor system that can readily alternate between transcription of two 
genes (or operons), dependent on the inducer present in the media (Litcofsky et al. 
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2012).  Advantages of this approach include the ability to fine tune expression levels 
and general reversibility, although such constructs are often large and inherently 
leaky.  To investigate this approach, a dual GFP-RFP construct will be evaluated (Figure 
5.4A).  Said system relies on the use of a previously developed toggle switch that can 
readily alternate between GFP and RFP expression.  In the absence of inducer (aTc), 
RFP transcription will be ‘on’ whereas GFP transcription will be ‘off’.  Following addition 
of inducer (aTc), RFP transcription will be ‘off’ and GFP transcription will be ‘on’ (Figure 
5.4B).  RFP and GFP expression over time will be evaluated to fully characterize the 
toggle switch system.  
The last transcriptional control approach to be investigated is the 
implementation of a dynamic chromosomal deletion cassette, modeled after the 
traditional chromosomal gene deletion strategy (Figure 5.5) (Datsenko and Wanner 
2000).  Traditional chromosomal gene deletions (Figure 5.5A) typically result in the 
greatest overall impact to increasing titer and yield by eliminating competing pathway 
CRISPRi
gDNA
Transcription 
blocked
gDNA
RNA Pol.
sgRNA dCas9
PIND PON
A
B
sgRNA + dCas9
Figure 5.3  Synthetic CRISPRi.  (A) Custom designed circuits will be engineered for 
controllable sgRNA and dCas9 expression. (B) Synthetic CRISPRi circuits will be tested 
for GFP transcriptional repression. 
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flux.  Gene deletions are most commonly constructed via homologous recombination 
using a selectable marker (kanamycin or chloramphenicol resistance) flanked by FRT 
sites.  Although this method is well established and highly effective at reducing 
competing pathway flux, gene deletions remain limited to non- and conditionally-
essential targets.  Expanding on this existing technology, the engineering and 
implementation of a dynamic chromosomal deletion system is proposed to impart flux 
control (Figure 5.5B).  Gene targets of interest, in this case GFP, will be chromosomally 
flanked by FRT sites.  Following expression of FLP recombinase, the FRT flanked gene 
target will be chromosomally deleted, resulting in a controllable phenotype switch.  
Whereas the original gene target must effectively be replaced with the FRT flanked 
variant, this strategy is inherently irreversible and therefore offers additional 
engineered microorganism biocontainment as the loss of an essential gene renders the 
host unviable at the end of culturing.  Analogous to the previously described 
approaches, GFP levels over time will be evaluated to characterize this phenotype 
switch.   
tetR
Ptet
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Plac
aTc
GFP
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Figure 5.4  Engineered Toggle Switch. (A) Metabolic toggle switch used to impart a 
sharp and efficient phenotype switch.  (B) Ideal phenotype switch output.  In the 
absence of aTc, cells express RFP.  Following addition of aTc, a phenotype switch is 
observed by the loss of RFP expression and presence of GFP expression. 
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5.1.2. Translational Control 
E. coli relies on a variety of RNA-mediated mechanisms to modulate gene 
expression through translational control, including attenuation mechanisms, 
riboswitches, and cis- and trans-encoded sRNA. Both attenuation mechanisms and 
riboswitches rely on complex secondary RNA self-interactions and/or metabolite 
binding under select environmental conditions. Whereas both methods effectively 
preclude ribosomal attachment and subsequent translation, these control mechanisms 
are difficult to design for metabolic engineering applications.  Meanwhile, cis-encoded 
sRNA (csRNA) is a small regulatory RNA transcribed from the sense DNA strand near 
the target gene. Because of the proximity, csRNA typically consists of lengthy target 
binding regions (~75 nucleotides) and secondary structures (up to 500 bp), resulting 
in complete sequences that overlap with the coding region of interest.  Although 
effective at blocking ribosomal binding, csRNA is therefore difficult to design and 
construct for metabolic engineering applications due to the chromosomal location.  
Finally, trans-encoded sRNA is transcribed at a distant location relative to the target 
gene. As these sRNA molecules are transcribed at various locations throughout the 
chromosome, each trans-encoded sRNA can have multiple gene targets, dependent on 
the target binding region. Accordingly, trans¬-encoded sRNA target binding sequences 
are readily predictable and are an ideal tool for modulating gene expression through 
translational control.  Although the sRNA constructs are small and require no additional 
host engineering, calculated fine tuning is required with added caution towards 
potential off-target effects. Accordingly, custom sRNA circuits will be designed to 
modulate GFP translational levels (Figure 5.6).  sRNA expression will be under control 
of an inducible promoter (Figure 5.6A).  One present, sRNA scaffolds are stabilized by 
native Hfq protein.   Stable sRNA scaffolds will bind to the mRNA at a pre-determined 
location, resulting in translational inhibition (Figure 5.6B). GFP levels will be evaluated 
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over-time to characterize the response and efficacy of sRNA as a phenotype control 
switch. 
 
5.1.3. Post-translational Control 
To demonstrate and characterize the use of post-translational control as a 
phenotype switch, tunable protein degradation will lastly be investigated.  E. coli 
contains several endogenous proteases that degrade select proteins labeled with 
specific amino acid tails.  Whereas variants of the amino acid tails result in dissimilar 
degradation rates, inducible control cannot be achieved without extensive host 
engineering.  More recently, a tunable protein degradation system that does not rely 
on native protease activity was developed in E. coli (Cameron and Collins 2014).  The 
system is based on a Mesoplasma florum transfer-messenger RNA system that allows 
for steady-state protein levels with tunable degradation via Lon protease (mf-Lon), 
sRNA
PIND
A
B
sRNA + Hfq
sRNA
Translation 
blocked
RNA Pol.
mRNA
Native Hfq
RNA Pol.
Figure 5.6  Small Synthetic Regulatory RNA (sRNA). (A) Synthetic sRNA circuits will 
be engineered for custom designed sRNA expression.  sRNA transcripts are stabilized 
by native Hfq protein binding.  (B) Synthetic sRNA constructs will be evaluated for the 
translational repression of GFP. 
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does not require disruption of the host organism’s native protein degradation 
mechanisms, and can be seamlessly integrated for the targeted proteolysis of protein 
variants containing a specific degradation tag.  To demonstrate this approach as a 
dynamic phenotype switch, native GFP will be replaced with a custom tagged GFP 
variant and evaluated for degradation following expression of the mf-Lon protease 
(Figure 5.7).  Successful proteolysis will be determined by evaluating GFP expression 
levels following mf-Lon protease induction. 
 
 
5.1.4. Phenotype Switch Design Considerations 
To achieve complete repression of GFP expression, several design 
considerations will be implemented.  In the case of CRISPRi, an important design 
element is the sequence of the custom sgRNA.  Here, a 20-25 nucleotide base-pairing 
region will be used as this has been found to be sufficient for high binding energy with 
the target nucleotide sequence.  For example, when co-expressed with dCas9, an 
sgRNA with 20 nucleotides of complementarity has been shown to result in up to 
99.9% transcriptional repression.  Repression of transcription has also been reported 
Protease
Native protein + 
degradation tag
mf-Lon
PIND
Protease
Figure 5.7  Tunable Protein Degradation. mf-Lon mediated protein degradation 
achieved via custom tagged proteins containing a custom designed C-terminus amino 
acid tail (e.g. pdt#3). 
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to be the strongest when the selected binding site is positioned close to or on the 
transcription start site of the target gene.  In this case, several binding locations will 
be comparatively evaluated to identify that which confers the greatest repression 
efficiency.  Finally, the base-pairing region should also be designed to minimize off-
target binding as such occurrences can unpredictably impact host function.  In silico 
design tools (e.g. E-CRISP, sgRNAcas9) will be used to help ensure target site 
specificity.  With these factors in mind, a comprehensive pool of candidate sgRNA 
sequences will be designed, synthesized, and comparatively screened (further 
described below) to identify the most effective design strategy.  Preliminary data using 
CRISPRi for MA production is contained in Appendix D.  
 In the case of the metabolic toggle switch, an important design element is the 
complimentary promoter-repressor selection and induction level.  Here, a previously 
developed toggle switch will be used to effectively alternate between RFP and GFP 
expression.  Our system is comprised of a Plac-tetR-RFP and Ptet-lacI-GFP promoter-
repressor system.  In the absence of aTc, this system expresses tetR-RFP, thereby 
repressing lacI-GFP expression.  Following addition of aTc, tetR-RFP expression is 
repressed, allowing for lacI-GFP expression.  Furthermore, addition of IPTG can return 
the toggle switch to the original state (i.e. tetR-RFP expression, lacI-GFP repression).  
Accordingly, varying inducer levels (both aTc and IPTG) will be comparatively 
evaluated to identify that which confers complete expression and switch between RFP 
and GFP.  Preliminary data using a metabolic toggle switch for MA production is 
contained in Appendix D.  
Next, an important design element for the dynamic chromosomal deletion 
approach is expression of the FLP recombinase. In this case, in silico models have 
demonstrated that the FLP recombinase can reach maximum DNA excision levels 
approaching 100%. To achieve this high level of excision, promoter selection and 
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corresponding inducer levels will be investigated. In addition, plasmid copy number 
will be varied and comparatively evaluated to achieve as close to 100% excision as 
possible.   
 In the case of sRNA, a custom designed nucleotide base-pairing region must 
confer high binding energy with the target nucleotide sequence to result in adequate 
translational repression. The use of sRNA to dynamically control pathway flux has 
previously been implemented for the enhanced biosynthesis of tyrosine and 
cadaverine, resulting in the production of 2 g/L tyrosine and a 55% increase in 
cadaverine production relative to the control.  In this case, a 20-30 nucleotide region 
and a target binding energy between -30 and -40 kcal/mol was required to achieve 
greater than 95% translational repression of select gene targets. Levels of translational 
repression were further dependent on the location of the binding site relative to the 
ribosomal binding site. In this case, several binding energies and locations will be 
comparatively evaluated (as determined using the in silico design tool DINAmelt) to 
identify the combination that results in the highest translational repression. Finally, 
the target binding region should also be designed to reduce unwanted off-target 
effects.  Here, off target binding energies less than -10 kcal/mol have been reported 
to have no ill effect on overall host function. The in silico design tool TargetRNA2 will 
be used to ensure target binding specificity. With these factors in mind, a 
comprehensive pool of sRNA sequences will be comparatively evaluated to determine 
the most efficient system for translational control.  
 Finally, tunable post-translational control will be investigated by evaluating GFP 
degradation rates.  In this case, a tagged GFP variant that results in rapid and efficient 
degradation in the presence of exogenous mf-Lon protease will be constructed.  
Tagged variants have previously been reported to be stable in the absence of mf-Lon 
protease, while levels of degradation are controlled by the 27 amino acid tail added to 
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the C-terminus of the protein.  In this case, the previously reported pdt-#3 tag will be 
investigated first, as this sequence resulted the in rapid (< 6 hours) and complete loss 
of the targeted protein. Additional rates and levels of protein degradation will be 
investigated by altering the C-terminus tag sequence. In addition, various promoter 
strengths and plasmid copy number driving mf-Lon protease expression will be 
investigated to fine tune degradation rates and levels.    
 
5.1.5. Phenotype Switch Characterization 
As mentioned previously, the ideal phenotype control system will result in the 
rapid loss of GFP expression and subsequent depletion of detectable GFP levels.  
Accordingly, the in vivo function of all proposed dynamic phenotype switches will first 
be comprehensively examined with respect to their kinetic and equilibrium behaviors 
using a suite of analytical tools.  Using the initial GFP-based systems, a dynamic 
phenotype switch capable of a rapid and sharp phenotype transition will be identified.  
In addition to the design considerations outlined above, several other relevant factors 
will also be explored to first understand and then optimize their effect.  In addition to 
culture temperature, the role of induction strength and timing (i.e. exponential vs. 
stationary phase) will be of interest.  A preliminary assessment of the function and 
efficacy of the different dynamic phenotype switches will easily be gained from 
monitoring the relative GFP expression levels via a custom designed plate reader assay 
and/or flow cytometry.  Efficient repression of GFP expression (i.e. transcriptional and 
translational repression) will result in steady-state GFP levels equivalent to those 
observed at the time of dynamic phenotype switch induction.  Efficient loss of GFP 
expression (i.e. post-translational repression) will result in the complete loss of 
detectable GFP levels.  More detailed analyses will subsequently be performed for the 
most promising phenotype switch designs (i.e. sgRNA sequences, sRNA sequences, 
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degradation tag, etc.) and conditions (i.e. induction strength and timing).  Quantitative 
real-time PCR will be used to determine the rate and efficiency by which GFP 
transcription and translation are repressed.  Western blot analysis will be performed 
to determine the rate and extent of tagged GFP degradation.  Finally, in all cases, 
biomass and cell viability will be monitored using optical density measurements 
(OD600) and commercially available cell viability kits, respectively to gain a preliminary 
insight regarding possible phenotype switch impacts to overall host fitness. 
 
5.1.6. Anticipated Outcomes 
The proposed dynamic phenotype switches described above all share the same 
desired output (Figure 5.8). However, while the complete loss of further GFP 
expression and detection is desirable, it is possible that the subsequent complete 
absence of GFP may not be achieved via the implementation of the transcriptional and 
translational approaches.  In these cases, GFP levels are expected to remain similar to 
those present at the time of phenotype switch induction.  It should be noted that, while 
residual GFP does not impact our test system, residual competing pathway genes (as 
represented by GFP) would result in an ineffective flux redistribution system with little 
observable impact on final production metrics, as further discussed in the subsequent 
sections. To this end, a combination of the approaches described above may ultimately 
be required to achieve a phenotype switch with the ideal response.  For example, 
CRISPRi and protein degradation are hypothesized to result in a more desirable (ideal) 
response.    
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5.1.7. Pitfalls and Proposed Solutions 
Should initial challenges arise while investigating the various phenotype control 
switches outlined above, initial proposed solutions will be implemented.  CRISPRi and 
sRNA mediated phenotype switches may be leaky and result in undesirable GFP 
repression prior to system induction.  Should this be the case, alternative promoters 
and/or promoter-repressor systems will be investigated to more tightly regulate 
expression.  Meanwhile, while the clear majority of proteins in E. coli are reported to 
be accessible to mf-Lon proteolysis, select proteins have been reported to be stable in 
the presence of mf-Lon protease despite containing the pdt#3 degradation tag.  
Although the exact mechanism for avoiding degradation is unknown, protein folding 
and/or post-translational modifications are suspected causes.  Should this be the case, 
Time
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Single approach
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Figure 5.8  Dynamic Phenotype Switch Output. The ideal system (solid line) 
will result in a rapid and efficient response relative to the control (dash line), 
observed by the loss of detectable GFP.  Most individual techniques will likely 
result in steady-state GFP levels close to those detected at the time of 
phenotype switch induction (dash-dot line).  However, by combining more than 
one approach, a response (dash-dot-dot line) mirroring the ideal system is 
expected. 
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alternative protein degradation strategies, including native E. coli proteolysis 
mechanisms will be investigated.  In the case of the dynamic chromosomal deletion 
approach, less than 100% efficient GFP excision will result in two subpopulations 
containing and lacking GFP.  If necessary, strategies for controlled cell death will be 
investigated.  In this case, a toxin-antitoxin system will be investigated to enable 
survival only following successful recombination.  
 
5.2. Dynamic Flux Regulation for Phenol and MA Production 
Phenol and muconic acid (MA) are important platform chemicals, used as 
platform chemicals for the synthesis of plastics and polymers.  In the case of phenol, 
the complete biosynthesis from glucose has been reported stemming directly from 
endogenous chorismate.  By eliminating chorismate mutase activity, encoded by 
native pheA, significant phenol accumulation was realized. However, while this 
strategy increased the available intracellular pool of chorismate, disrupting native pheA 
necessitates phenylalanine supplementation in a minimal salts medium to support cell 
growth.  On the other hand, MA biosynthesis was first reported following the 
development of a three step pathway stemming from endogenous 3-dehydroshikimate 
(3DHS).  Although several other successful pathways have been engineered instead 
stemming from endogenous chorismate, the original route confers highest achievable 
yields.  Whereas 3DHS is a key intermediate metabolite in the shikimic acid pathway, 
significant MA overproduction requires the deletion of subsequent shikimate 
dehydrogenase, encoded by native aroE.  However, this strategy results in multiple 
essential vitamin auxotrophies, including phenylalanine, tyrosine, tryptophan, p-
aminobenzoate, p-hydroxybenzoate, and 2,3-dihydroxybenzoate. Consequently, all 
essential vitamins must be supplemented in a minimal salts media to support cell 
viability, ultimately leading to expensive media formulations and poor scalability.    
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As an alternative approach, the best two or three phenotype switches (as 
identified by the previous proposed work) to effectively simulate the traditional 
chromosomal deletion will be implemented for enhanced phenol and MA biosynthesis. 
Select phenotype switches will be implemented to the original MA pathway to modulate 
native aroE expression and in the case of phenol and the MA funneling pathway 
combination to modulate native pheA. By eliminating aroE and pheA expression, cells 
are hypothesized to shift carbon flux away from key nutrient pathways and towards 
MA and phenol production, resulting in non-growing cells.  Cells existing in a non-
growing yet metabolically active state can sustain high biosynthetic capacity.  For 
example, the exogenous addition of chloramphenicol (inhibits ribosome function) was 
previously demonstrated to decouple growth from phenylalanine production.  Although 
this approach resulted in a 50% greater specific productivity over the control strain, 
the high cost of antibiotics and growing concern of resistant mutants renders this 
approach impractical for biosynthetic applications.   
To evaluate the applicability of the select dynamic phenotype switches, related 
host backgrounds will be investigated. E. coli NST74 ∆aroE will serve as the established 
gene deletion control to evaluate the relative performance of the original 3DHS derived 
pathway, while E. coli NST74 ∆pheA will serve as the deletion control to evaluate the 
relative performance of phenol biosynthesis and the MA ‘funneling’ combination 
pathway.  Meanwhile, E. coli NST74, is a previously engineered phenylalanine 
overproducer (essential metabolite downstream of aroE and pheA) and will serve as 
the control strain for both MA biosynthesis routes.  For all the dynamic phenotype 
switches tested, this host will serve as an ideal test platform because efficient 
repression of shikimate dehydrogenase activity (encoded by aroE) and chorismate 
mutase (encoded by pheA) by any dynamic approach will result in reduced carbon flux 
toward phenylalanine. Accordingly, phenylalanine titers will be monitored and 
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compared to the control as one metric to determine effectiveness of each strategy 
utilized. In the case of sRNA and CRISPRi implementation, RT-PCR and/or qPCR can 
be used to evaluate relative expression levels and rate and efficiency of repression.  
Meanwhile, in the case of mf-Lon mediated protein degradation, while phenylalanine 
titers will provide useful insight, western-blot analysis will ultimately be required to 
confirm the degradation of AroE and PheA.  Depending on the outcomes (e.g. relative 
phenylalanine levels), the same tuning strategies as described previously (i.e. 
promoter strength, plasmid copy number, RBS, etc.) will be implemented to identify a 
host capable of achieving the dynamic characteristics closest to the ideal outcome.  
Finally, cell viability over the course of dynamic control strategy implementation will 
be evaluated using commercially available kits. 
 
5.3. Conclusions 
These works demonstrate the applicability of various dynamic phenotype 
switches as a control strategy for metabolic flux control.  Novel pathway design and 
construction enabled phenol and MA production while avoiding some of the inherent 
limitations associated with the original biosynthesis routes.  To further enhance 
production metrics, numerous dynamic flux control strategies, and combinations 
thereof, should be characterized and utilized as an alternative to traditional gene 
disruptions.   
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NATURAL PATHWAYS FOR MICROBIAL PHENOL PRODUCTION 
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Table A1  List of primers designed and used for phenol production 
Primer Sequence (5' → 3') 
tutA -- EcoRI - F ATA GAA TTC AGG AGG ATA AAT AAT GAA TTA TCC GGC AGA ACC  
tutA -- XbaI - R ATT TCT AGA TTA GAT ATA GTC AAA GCG TGC AGT A 
pchB -- XbaI - F AAT ATC TAG ATT CCC GAG AGG TTG CAT GAT GAA AAC T 
pchB -- BamHI - R ATT GGA TCC TTA TGC GGC ACC CCG TGT CTG G 
entC -- BamHI - F ATA GGA TCC AGG AGG ATA AAT AAT GGA TAC GTC ACT GGC TGA  
entC -- PstI - R ATT CTG CAG TTA ATG CAA TCC AAA AAC GTT  
SDC -- NcoI - F ATA CCA TGG AGG AGG ATA AAT AAT GCG TGG TAA AGT TAG CCT G 
SDC -- BamHI - R ATT GGA TCC TTA GGC TTC GCT GTC ATA GAA T 
ubiC -- EcoRI - F ATA GAA TTC AGG AGG ATA AAT AAT GTC ACA CCC CGC GTT AAC G 
ubiC -- BglII - R ATT AGA TCT TTA GTA CAA CGG TGA CGC CGG TAA A 
kpdBCD -- BamHI - F ATA GGA TCC CCC GTC CGG AGA GGG TAA TTT AAA TAT AAA GTT CG 
kpdBCD -- HindIII - R ATT AAG CTT CTT AGC GGG CCC CTT TAT TAA CGC T 
bsdBCD -- NcoI - F ATA CCA TGG CAG GAG TAT GAT TGA AAT GAA AGC AGA ATT CAA GC 
bsdBCD -- PstI - R ATT CTG CAG AAA GAG ACG GTC TGA CAT ACA GTT CAC GC 
aroC-aroA-aroL [pY3] -- F AGA TCT AAA GGA GGC CAT CCA TGG CTG GAA ACA CAA TTG G 
aroC-aroA-aroL [pY3] -- R ATG CCT GGA GAT CCT TAC TCG AGT TTG GAT CCT C 
pY3 [aroC-aroA-aroL] -- F GAG GAT CCA AAC TCG AGT AAG GAT CTC CAG GCA T 
pY3 [aroC-aroA-aroL] -- R CCA ATT GTG TTT CCA GCC ATG GAT GGC CTC CTT TAG ATC T 
 
 
Table A2  Comparing maximum product and biomass yields (reported as the fraction 
of carbon in the glucose substrate converted into phenol product) for each of the three 
engineered phenol pathways, as predicted using the wild-type E. coli network. 
 
Pathway 
EFM  
Count 
Max Product 
Yield 
Max Product 
Yield w/ Growth 
Max Biomass Yield 
Pathway 1 657,578 0.7448 0.6919 0.7086 
Pathway 2 481,279 0.7500 0.6755 0.7086 
Pathway 3 481,279 0.7500 0.6755 0.7086 
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Figure A1a  Product vs. biomass yield plot of the EFM distribution of synthesized via 
the tyrosine route, as predicted using the wild-type E. coli network. Product and 
biomass yields reported as the fraction of carbon in the glucose substrate converted 
into each product. 
 
 
 
Figure A1b  Product vs. biomass yield plot of the EFM distribution of synthesized via 
the p-hydroxybenzoate route, as predicted using the wild-type E. coli network. Product 
and biomass yields reported as the fraction of carbon in the glucose substrate 
converted into each product. 
117 
 
   
Figure A1c  Product vs. biomass yield plot of the EFM distribution of synthesized 
via the salicylate route, as predicted using the wi ld-type E. coli network. Product 
and biomass yields reported as the fraction of carbon in the glucose substrate 
converted into each product. 
 
 
 
Figure A2  Conversion of tyrosine (open square) to phenol (solid square) by E. coli 
BW25113 pTutA whole resting cells.  Error bars represent one standard deviation 
from triplicate experiment.  
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Figure A3b  Networks and functions used for elementary flux mode analysis of phenol 
biosynthesis via tyrosine. 
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Figure A3b  Networks and functions used for elementary flux mode analysis of phenol 
biosynthesis via salicylate. 
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Figure A3c  Networks and functions used for elementary flux mode analysis of phenol 
biosynthesis via p-hydroxybenzoate.  
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APPENDIX B 
SUPPLEMENTAL INFORMATION TO ENGINEERING NOVEL PATHWAYS FOR THE 
BIOSYNTHESIS OF MUCONIC ACID 
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Table B1  List of primers designed and used for catechol and muconic acid production 
Primer Sequence (5' → 3') 
qsuB -- BamHI - F ATA GGA TCC AGG AGG ATA AAT AAT GCG TAC ATC CAT TGC CAC TGT TTG  
qsuB -- HindIII - R ATT AAG CTT CTA GTT TGG GAT TCC CCG CTC GA 
catA – BglII -F ATA AGA TCT AGG AGG ATA AAT AAT GAC CGT GAA AAT TTC CCA C 
catA -- XbaI - R ATT TCT AGA TCA GCC CTC CTG CAA CGC 
tutA -- EcoRI - F ATA GAA TTC AGG AGG ATA AAT AAT GAA TTA TCC GGC AGA ACC 
tutA -- XbaI - R ATT TCT AGA TTA GAT ATA GTC AAA GCG TGC AGT A 
SDC -- EcoRI - F ATA GAA TTC AGG AGG ATA AAT AAT GCG TGG TAA AGT TAG CCT G 
SDC - BamHI - R ATT GGA TCC TTA GGC TTC GCT GTC ATA GAA T 
pchB -- XbaI - F AAT ATC TAG ATT CCC GAG AGG TTG CAT GAT GAA AAC T 
pchB -- BamHI - R ATT GGA TCC TTA TGC GGC ACC CCG TGT CTG G 
entC -- BamHI - F ATA GGA TCC AGG AGG ATA AAT AAT GGA TAC GTC ACT GGC TGA  
entC -- PstI - R ATT CTG CAG TTA ATG CAA TCC AAA AAC GTT  
ubiC -- EcoRI - F ATA GAA TTC AGG AGG ATA AAT AAT GTC ACA CCC CGC GTT AAC G 
ubiC -- BglII - R ATT AGA TCT TTA GTA CAA CGG TGA CGC CGG TAA A 
kpdBCD -- BamHI - F ATA GGA TCC CCC GTC CGG AGA GGG TAA TTT AAA TAT AAA GTT CG 
kpdBCD -- HindIII - R ATT AAG CTT CTT AGC GGG CCC CTT TAT TAA CGC T 
phKLMNOP -- XbaI - F ATA TCT AGA AGG AGG ATA AAT AGA GCT CGT GCT GCC TCA CGA  
phKLMNOP -- SbfI - R ATT CCT GCA GGA TGC CCA TGA CTA TAT CTT CTT GAA CAG GGC  
pheA (Keio) -- F CGT GTG AAA CAG AAT GCG AAG ACG AAC AAT A 
pheA (Keio) -- R TAA TCC AGT GCC GGA TGA TTC ACA TCA TC 
 
 
 
 
 
 
Figure B1a. Product vs. biomass yield plot of the EFM distribution of muconic acid 
synthesized via the pathway MA1, as predicted using the wi ld-type E. coli network. 
Product and biomass yields reported as the fraction of carbon in the glucose 
substrate converted into each product. 
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Figure B1b. Product vs. biomass yield plot of the EFM distribution of muconic 
acid synthesized via the pathway MA2, as predicted using the wi ld-type E. coli 
network. Product and biomass yields reported as the fraction of carbon in the 
glucose substrate converted into each product. 
 
 
 
Figure B1c. Product vs. biomass yield plot of the EFM distribution of muconic acid 
synthesized via the pathway MA3, as predicted using the wi ld-type E. coli network. 
Product and biomass yields reported as the fraction of carbon in the glucose 
substrate converted into each product. 
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Figure B1d. Product vs. biomass yield plot of the EFM distribution of muconic 
acid synthesized via the pathway MA4, as predicted using the wi ld-type E. coli 
network. Product and biomass yields reported as the fraction of carbon in the 
glucose substrate converted into each product. 
 
 
 
Figure B1e. Product vs. biomass yield plot of the EFM distribution of muconic acid 
synthesized via the pathway MA5, as predicted using the wi ld-type E. coli network. 
Product and biomass yields reported as the fraction of carbon in the glucose 
substrate converted into each product. 
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Figure B2.  Detection of 1,2,3-trihydroxybenzene (1,2,3-THB) in culture supernatants 
from E. coli BW25113 whole resting cells expressing phKLMNOP of Pseudomonas 
stutzeri OX1.  Cells were suspended in PBS buffer (pH 6.8) supplemented with 1 mM 
phenol.  
 
 
 
 
Figure B3. Effect of the exogenous addition of 1,2,3-trihydroxybenzene on the growth 
of E. coli NST74 ∆pheAfbr when added to early exponential cultures at final 
concentrations of 0 g/L (■ ), 1 g/L (●), 2 g/L (▲), 3 g/L (♦ ), 4 g/L (♦ ), 5 g/L (x), and 
6 g/L (+).  Error bars represent one standard deviation from triplicate experiment.  
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Figure B4a  Networks and functions used for elementary flux mode analysis of 
muconic acid biosynthesis via MA1. 
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Figure B4b  Networks and functions used for elementary flux mode analysis of 
muconic acid biosynthesis via MA2. 
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Figure B4c  Networks and functions used for elementary flux mode analysis of 
muconic acid biosynthesis via MA3. 
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Figure B4d  Networks and functions used for elementary flux mode analysis of 
muconic acid biosynthesis via MA4. 
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Figure B4e  Networks and functions used for elementary flux mode analysis of 
muconic acid biosynthesis via MA5.  
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APPENDIX C 
SUPPLEMENTAL INFORMATION TO EXPLORING A SYNTHETIC METABOLIC 
FUNNELING APPROACH TO ENHANCE PHENOL AND MUCONIC ACID BIOSYNTHESIS 
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Table C1  List of primers designed and used for phenol and muconic acid production 
Primer Sequence (5' → 3') 
qsuB -- BamHI - F ATA GGA TCC AGG AGG ATA AAT AAT GCG TAC ATC CAT TGC CAC TGT TTG  
qsuB -- HindIII - R ATT AAG CTT CTA GTT TGG GAT TCC CCG CTC GA 
catA -- BglII-F ATA AGA TCT AGG AGG ATA AAT AAT GAC CGT GAA AAT TTC CCA C 
catA -- XbaI - R ATT TCT AGA TCA GCC CTC CTG CAA CGC  
ubiC -- EcoRI - F ATA GAA TTC AGG AGG ATA AAT AAT GTC ACA CCC CGC GTT AAC G 
ubiC -- BglII - R ATT AGA TCT TTA GTA CAA CGG TGA CGC CGG TAA A 
kpdBCD -- BamHI - F ATA GGA TCC CCC GTC CGG AGA GGG TAA TTT AAA TAT AAA GTT CG 
kpdBCD -- HindIII - R ATT AAG CTT CTT AGC GGG CCC CTT TAT TAA CGC T 
pY3 [tutA] - F CTG CAC GCT TTG ACT ATA TCT AAG GAT CCA AAC TCG AGT AAG G 
pY3 [tyrA] - R CAT GGA TGG CCT CCT AGA TCT TTT GAA TTC TGA AAT TGT TAT C 
tyrA [pY3] - F GAT AAC AAT TTC AGA ATT CAA AAG ATC TAG GAG GCC ATC CAT G 
tyrA [tutA] - R CGG ATA ATT CAT TAT TTA TCC TCC TTT AGA TCC TTA CTG GCG ATT  
tutA [tyrA] - F AAT CGC CAG TAA GGA TCT AAA GGA GGA TAA ATA ATG AAT TAT CCG 
tutA [pY3] - R CCT TAC TCG AGT TTG GAT CCT TAG ATA TAG TCA AAG CGT GCA G 
SDC-pchB-entC [pS3] -- F AAG GAG GCC ATC CAT GCG TGG TAA AGT TAG C 
SDC-pchB-entC [pS3] -- R GTT TGG ATC CTT AAT GCA ATC CAA AAA CG 
pS3 [SDC-pchB-entC] -- F ATT GCA TTA AGG ATC CAA ACT CGA GTA AG 
pS3 [SDC-pchB-entC] -- R CTT TAC CAC GCA TGG ATG GCC TCC TTT AGA TC 
pheA (Keio) -- F CGT GTG AAA CAG AAT GCG AAG ACG AAC AAT A 
pheA (Keio) -- R TAA TCC AGT GCC GGA TGA TTC ACA TCA TC 
pykA (Keio) -- F ATC GCG GCG TTA TTT CAT TCG GAT T 
pykA (Keio) -- R AAC TGT AGG CCG GAT GTG GC 
pykF (Keio) -- F GCG AGG CAC CAC CAC TTT CG 
pykF (Keio) -- R AGC GCC CAT CAG GGC G 
crr (Keio) -- F CTA TGA GCG CCA TTT CTA TCC CGC GC 
crr (Keio) -- R CCT GAA AGG GAC TGG CGA CCT G 
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APPENDIX D 
PRELIMINARY DATA SUPPORTING THE ENGINEERING OF A DYNAMIC PHENOTYPE 
CONTROL SWITCH  
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Investigating Transcriptional Control Using a Metabolic Toggle Switch 
 To improve MA biosynthesis, a metabolic toggle switch was constructed (Figure 
D1 and Figure D2) to modulate expression between native shikimate dehydrogenase 
(encoded by aroE) and the original heterologous muconic acid biosynthesis pathway 
(encoded by qsuB, aroY, and catA).  As illustrated in Figure D2, the toggle will express 
the MA pathway and repress expression of aroE in the presence of aTc.  In contrast, 
the toggle will express aroE and repress MA pathway expression in the presence of 
IPTG.  To test functionality, said toggle was transformed into E. coli NST74 ∆aroE and 
evaluated against appropriate control strains (Table D1).  Strains were cultured at 
32ºC in baffled shake flasks using 50 mL of a phosphate-limited minimal media (MM1) 
composed of (concentrations in parentheses, all in g/L): MgSO4·7H2O (0.5), (NH4)2SO4 
(4.0), MOPS (24.7), KH2PO4 (0.3), K2HPO4 (0.7), (NH4)6Mo7O24∙4H2O (3.7·10-4), H3BO3 
(2.5·10-3), CoCl2∙6H2O (7.14·10-4), CuSO4 (1.6·10-4), MnCl2∙4H2O (1.6·10-3), 
ZnSO4∙7H2O (2.88·10-4), FeCl3 (5.0·10-5), and glucose (20), supplemented with 
appropriate antibiotics.  E. coli NST74 ∆aroE strains lacking the metabolic toggle 
plasmid were additionally supplemented with 100 mg/L each of Phe, Tyr, Trp, and 50 
mg/L each of p-hydroxybenzoate, p-aminobenzoate, and 2,3-dihydroxybenzoate.  To 
induce aroE or qsuB-aroY-catA expression, IPTG and/or aTc were added at final 
concentrations of 0.4 mM and 400 nM, respectively, when cells reached an OD600 of ~ 
0.7.  Although MA was produced using the metabolic toggle design depicted in Figure 
D1, significant room for improvement remains.  Additional characterization should be 
investigated initially focused on GFP-mCherry levels, varying levels of inducer, and 
varying time point at which inducer is added.   
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Figure D1  Plasmid map illustrating the metabolic toggle switch for MA production 
pKDL -- aroE -- qsuB-aroY-catA
10812 bp
GFP
lacI
tetR
mCherry
Kan(r)
aroE
qsuB
aroY
catA
Ptet
Plac
pBR322 ori
rmb T1 terminator
Figure D2  Engineered metabolic toggle switch design.  Addition of aTc results in 
MA pathway (qsuB-aroY-catA) expression, while addition of IPTG results in native 
aroE expression. 
tetR
Ptet
aroE
lacI
Plac
aTc
qsuB
IPTG
aroY catA
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Table D1  Plasmids used in this study 
 
Plasmid Description Source 
pKDL pBR322 ori, Kanr, Ptet-lacI-GFP, Plac-tetR-mCherry Xiao Wang Lab (ASU) 
pMA 
pBR322 ori, Kanr, Ptet-lacI-qsuB-aroY-catA-GFP, Plac-tetR-
aroE-mCherry 
This study 
 
 
Table D2  MA production using metabolic toggle switch 
 
Strain Plasmid Inducer Added OD600 MA (mg/L) 
NST74 ∆aroE -- none 3.2 n.d. 
NST74 ∆aroE pMA none 1.2 n.d. 
NST74 ∆aroE pMA aTc 2.2 229 
NST74 ∆aroE pMA IPTG 2.1 122 
 
 
 
Investigating Transcriptional Control Using CRISPRi 
 
To improve MA biosynthesis, a CRISPRi plasmid combination was engineered 
to transcriptionally repress native shikimate dehydrogenase (encoded by aroE).  To 
achieve repression, one plasmid harbors the custom designed sgRNA sequence (ATG 
GAA ACC TAT GCT GTT TT) under control of the strong constitutive promoter J23119 
(Figure D3) while dcas9 expression was under control of the inducible Ptet promoter 
(Figure D4).  In addition, MA production was achieved via expression of qsuB-aroY-
catA under control of the inducible Ptrc promoter (Figure D5).  To test functionality, the 
two CRISPRi vectors and the MA pathway vector were transformed into E. coli NST74 
and evaluated against appropriate control strains (Table D3). Strains were cultured at 
32ºC in baffled shake flasks using 50 mL of a phosphate-limited minimal media (MM1) 
composed of (concentrations in parentheses, all in g/L): MgSO4·7H2O (0.5), (NH4)2SO4 
(4.0), MOPS (24.7), KH2PO4 (0.3), K2HPO4 (0.7), (NH4)6Mo7O24∙4H2O (3.7·10-4), H3BO3 
(2.5·10-3), CoCl2∙6H2O (7.14·10-4), CuSO4 (1.6·10-4), MnCl2∙4H2O (1.6·10-3), 
ZnSO4∙7H2O (2.88·10-4), FeCl3 (5.0·10-5), and glucose (20), supplemented with 
appropriate antibiotics. To induce CRISPRi-mediated aroE repression and qsuB-aroY-
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catA expression, aTc and/or IPTG were added at final concentrations of 400 nM and 
0.4 mM, respectively, when cells reached an OD600 of ~ 0.7.  Although MA production 
remained unchanged with the use of CRISPRi, significant room for improvement 
remains.  Additional characterization should be investigated initially focused varying 
induction timing and alternative expression platforms for the sgRNA and dcas9 
components.  
 
 
Figure D3  Plasmid map for sgRNA expression targeting native aroE. 
 
 
pgRNA aroE
2584 bp
Amp
JAD designed chimera RNA 3' UTR (dCas9 handle)
tracrRNA terminator
J23119 (SpeI) Promoter
Terminator rrnB
ColE1 ori
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Figure D4  Plasmid map for dcas9 expression. 
 
 
 
Figure D5  Plasmid map for MA production via expression of qsuB-aroY-catA. 
 
pdCas9
6705 bp
Cmp
dCas9
tetR
PLtetO-1
dbl. terminator
p15A ori
pTrcCOLAK -- qsuB - aroY - catA
8281 bp
lacIq
KAN
qsuB
aroY
catA
Ptrc
ColA ori
Terminator
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Table D3  Plasmids used in this study 
 
Plasmid Description Source 
pgRNA colE1 ori, Ampr, PJ23119-gRNA(aroE) This study 
pdCAS9 p15A ori, Cmpr, tetR-Ptet-dCAS9 This study 
pMA ColA ori, Kanr, lacIq-Ptrc-qsuB-aroY-catA This study 
 
 
Table D4  MA production using CRISPRi 
 
Strain Plasmid OD600 Phenylalanine (mg/L) MA (mg/L) 
NST74 -- 3.0 1150 n.d. 
NST74 pMA 2.7 539 1592 
NST74 pgRNA, pdCAS9 2.8 796 n.d. 
NST74 pgRNA, pdCAS9, pMA 2.5 458 1452 
 
